17th ECCO - 38th ESMO - 32nd ESTRO
European Cancer Congress
Reinforcing multidisciplinarity
AMSTERDAM, 27 SEPTEMBER - 1 OCTOBER 2013
ADVANCE PROGRAMME
The Organising Committee gratefully acknowledges the support and collaboration of all Member Societies of ECCO, the European CanCer organisation, without which this Congress would not be possible.

Acknowledgement

Full members

- European Association of Nuclear Medicine (EANM)
- European Society of Breast Cancer Specialists (EUSOMA)
- European Society of Oncology Pharmacy (ESOP)

Advisory members

- Breast International Group (BIG)
- European Association of Urology (EAU)
- European Association of Nuclear Medicine (EANM)
- European Group of Blood and Marrow Transplantation (EBMT)
- European Organisation for Research and Treatment of Cancer (EORTC)
- Association of European Cancer Leagues (ECL)
- Organisation of European Cancer Institutes (OECI)
- International Union against Cancer (UICC)

Breast International Group (BIG)

European Association of Nuclear Medicine (EANM)

European Group of Blood and Marrow Transplantation (EBMT)

European Organisation for Research and Treatment of Cancer (EORTC)

Association of European Cancer Leagues (ECL)

Organisation of European Cancer Institutes (OECI)

International Union against Cancer (UICC)

Official Media Partners

On behalf of the Executive Scientific Committee, we gratefully acknowledge the collaboration and support of our official media partners for the European Cancer Congress 2013:
# Table of Contents

## Save the Dates

## Chair's Introduction

## European Cancer Congress 2013 Committees

### Scientific Programme – Programme at a Glance

- **Satellite Symposia**
- **Saturday, 28 September 2013**
- **Sunday, 29 September 2013**
- **Monday, 30 September 2013**
- **Tuesday, 1 October 2013**

## Detailed Advance Programme

## Young Oncologists @ ECC 2013

## Programme Tracks, Chairs and Experts

## Call for Abstracts

- **Abstract Policies & Regulations**
- **Abstract Preparation & Submission**
- **Abstract Selection Process**
- **Late-Breaking Abstracts - Policy & Regulations**
- **Embargo Policy for Late-Breaking, Oral Presentations and Abstracts Selected for Media**
- **Abstract Topic Categories**

## Fellowship Grants & Educational Awards

## Registration

## Exhibition & Sponsorship

## Exhibitor Spotlight Theatre

## General Information

## Top 10 Reasons to Attend ECC 2013
Save the Dates

European Cancer Congress 27 September – 1 October, 2013

**REGISTRATION DEADLINES**

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early rate registration opens</td>
<td>1 October 2012</td>
</tr>
<tr>
<td>Early rate registration closes (receipt of payment by)</td>
<td>9 April 2013</td>
</tr>
<tr>
<td>Regular rate registration opens</td>
<td>10 April 2013</td>
</tr>
<tr>
<td>Regular rate registration closes (receipt of payment by)</td>
<td>6 August 2013</td>
</tr>
<tr>
<td>Late rate registration opens</td>
<td>7 August 2013</td>
</tr>
<tr>
<td>Late rate registration closes</td>
<td>20 September 2013</td>
</tr>
<tr>
<td>Onsite registration as of</td>
<td>21 September 2013</td>
</tr>
</tbody>
</table>

**SUBMISSION DEADLINES**

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular abstract submission opens</td>
<td>25 January 2013</td>
</tr>
<tr>
<td>Regular abstract submission closes</td>
<td>17 April 2013</td>
</tr>
<tr>
<td>Fellowship grant application opens</td>
<td>25 January 2013</td>
</tr>
<tr>
<td>Fellowship grant application closes</td>
<td>17 April 2013</td>
</tr>
<tr>
<td>Late-breaking abstract submission opens</td>
<td>24 July 2012</td>
</tr>
<tr>
<td>Late-breaking abstract submission closes</td>
<td>7 August 2013</td>
</tr>
</tbody>
</table>

**HOUSING**

<table>
<thead>
<tr>
<th>Event</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Housing reservation closes</td>
<td>15 August 2013</td>
</tr>
</tbody>
</table>

**Secretariat & Venue**

**Congress secretariat:**
c/o ECCO – the European CanCer Organisation
Avenue E. Mounier 83
B-1200 Brussels
Telephone: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
Email: ecc2013@ecco-org.eu

**Congress Venue:**
Amsterdam RAI
Europaplein, 1078 AZ Amsterdam,
The Netherlands
Detailed information about the venue: www.rai.nl
Chair’s Introduction

The 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress will be held in Amsterdam, 27 September – 1 October 2013. It will be the latest in a prestigious biennial series of meetings that have been growing in appeal and outreach across all disciplines and organisations since its inception in 1981. Involving ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE, the European Cancer Congress forms a powerful combination for endorsing multidisciplinarity. And the statistics report demonstrates that participation is consistently expanding so that the meeting has become the largest, truly multidisciplinary gathering in Europe. Delivering a pioneering programme, this Congress will reinforce multidisciplinarity as optimal professional efficiency in practice.

At Amsterdam, all partner organisations will unite once again to continue positioning multidisciplinarity as the way forward to best improve the prevention, diagnosis, treatment and care of cancer patients. The comprehensive Scientific Programme of excellence is being devised by leading scientific experts in all fields, ensuring exceptional quality and educational opportunity. The wide-ranging Scientific Tracks guarantee a multi-professional appeal unique to the European Cancer Congress, creating a level playing field for all stakeholders in oncology. Consisting of 33 Tracks, the programme spans the entire oncology spectrum from basic, applied and translational research to practice, treatment, care, prevention and advocacy for cancer patients.

Central to this are the dynamic collaboration, engaging interaction and open exchange that this foremost event is renowned for achieving. And its recognised multidisciplinary setting will provide ideal surroundings for participants to leverage knowledge, promote education and build awareness about oncology - placing the patient at the heart of all our efforts and discussions.

The Congress also promises further outreach and education potential for the wider oncology community. It is the largest CME ACOE Accredited event in Europe, guaranteeing high quality and unbiased educational activities. The credits gained are recognised by most national CME authorities in Europe.

You can see from this detailed Advance Programme that the Congress also strives to further the role of multidisciplinary oncology by encouraging participation and interaction between all oncology professions, irrespective of their focus. We therefore strongly encourage involvement across disciplines and specialist fields and invite you to join our efforts to advance cancer treatment and care by ensuring your discipline or specialist field is well-represented. There is no better way to underpin the importance of your specialty and ensure it makes a tangible contribution in establishing standards for the field of oncology now and into the future.

In 2011, 15 931 participants convened to discuss, debate and deliberate the best possible treatment and care for cancer patients. We are confident that this next Congress will build on our successful track record and invite you to join us once again and play your part in solving the many unanswered questions and issues in cancer.

Cornelis van de Velde, Congress Chair, ECCO President
Martine Piccart, ESMO President
Vincenzo Valentini, ESTRO President
Cora Sternberg, Co-scientific Chair
John Yarnold, Co-scientific Chair
Marcel Verheij, National Organising Committee Chair
### European Cancer Congress 2013 Committees

#### Executive Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornelis van de Velde</td>
<td>Congress Chair, ECCO President</td>
</tr>
<tr>
<td>Martine Piccart</td>
<td>ESMO President</td>
</tr>
<tr>
<td>Cora Sternberg</td>
<td>Co-scientific Chair</td>
</tr>
<tr>
<td>John Yarnold</td>
<td>Co-scientific Chair</td>
</tr>
</tbody>
</table>

#### Organising Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornelis van de Velde</td>
<td>Congress Chair, ECCO President</td>
</tr>
<tr>
<td>Martine Piccart</td>
<td>ESMO President, ECCO President Elect</td>
</tr>
<tr>
<td>Vincenzo Valentini</td>
<td>ESTRO President</td>
</tr>
<tr>
<td>Ruth Ladenstein</td>
<td>ECCO Treasurer</td>
</tr>
<tr>
<td>Cora Sternberg</td>
<td>Co-scientific Chair</td>
</tr>
<tr>
<td>John Yarnold</td>
<td>Co-scientific Chair, Medical Oncology Vice Chair</td>
</tr>
<tr>
<td>Marcel Verheij</td>
<td>National Organising Committee Chair</td>
</tr>
</tbody>
</table>

#### National Organising Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcel Verheij</td>
<td>National Organising Committee Chair</td>
</tr>
<tr>
<td>Hans Gelderblom</td>
<td>Medical Oncology Vice Chair</td>
</tr>
<tr>
<td>Michel Wouters</td>
<td>Surgical Oncology Vice Chair</td>
</tr>
<tr>
<td>Cornelis van de Velde</td>
<td>Congress Chair</td>
</tr>
<tr>
<td>Paul Baas</td>
<td>Robertus Tollenaar</td>
</tr>
<tr>
<td>Regina G.H. Beets-Tan</td>
<td>Winette T.A. van der Graaf</td>
</tr>
<tr>
<td>Hans Clevers</td>
<td>Koos van der Hoeven</td>
</tr>
<tr>
<td>Elisabeth G.E. de Vries</td>
<td>Elsken van der Wall</td>
</tr>
<tr>
<td>Harald J. Hoekstra</td>
<td>Ate van der Zee</td>
</tr>
<tr>
<td>Cora Honing</td>
<td>Hans van Krieken</td>
</tr>
<tr>
<td>Philippe L. Lambin</td>
<td>Jaap Verweij</td>
</tr>
<tr>
<td>René Medema</td>
<td>Fred Witjes</td>
</tr>
</tbody>
</table>
## Executive Scientific Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Yarnold</td>
<td>Co-scientific Chair</td>
</tr>
<tr>
<td>Cora Sternberg</td>
<td>Co-scientific Chair</td>
</tr>
<tr>
<td>Yossi Yarden</td>
<td>Basic Science Vice Chair</td>
</tr>
<tr>
<td>Graeme Poston</td>
<td>Surgical Oncology Vice Chair</td>
</tr>
<tr>
<td>Cornelis van de Velde</td>
<td>Congress Chair, ECCO President</td>
</tr>
<tr>
<td>Martine Piccart</td>
<td>ESMO President</td>
</tr>
<tr>
<td>Marcel Verheij</td>
<td>National Organising Committee Chair</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Satellite Symposium Sanofi</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium Boehringer Ingelheim</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Satellite Symposium Sanofi</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium AstraZeneca</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Satellite Symposium Millennium</td>
</tr>
<tr>
<td>13:00 - 16:00</td>
<td>Satellite Symposium Novartis Oncology</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium Roche</td>
</tr>
<tr>
<td>14:00 - 16:00</td>
<td>Satellite Symposium Amgen</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium Celgene</td>
</tr>
<tr>
<td>14:00 - 16:00</td>
<td>Satellite Symposium Pfizer</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium Teva Santé</td>
</tr>
<tr>
<td>14:00 - 16:00</td>
<td>Satellite Symposium MSD Oncology</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>Satellite Symposium Lilly Oncology</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium Novartis Oncology</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>Satellite Symposium Celgene</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>Satellite Symposium Boehringer Ingelheim</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>Satellite Symposium Bayer Health care</td>
</tr>
<tr>
<td>17:00 - 19:00</td>
<td>Satellite Symposium Prime Oncology</td>
</tr>
<tr>
<td>19:15 - 21:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td></td>
<td>BIG Session: INTEGRATE: The potential of Data Sharing 16:45-18:45</td>
</tr>
</tbody>
</table>
### Saturday, 28 September 2013

#### Scientific Programme at a Glance

#### Opening Session

- 09:00-11:00 Biological Basis of Personalised Cancer Therapy

#### Session 1 (09:00-11:00)

- **Biological Basis of Personalised Cancer Therapy**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

- **Presidential Lecture**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

#### Session 2 (11:15-13:15)

- **Personalised Cancer Therapy**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

- **Mentorship**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

#### Session 3 (13:15-15:15)

- **Personalised Cancer Therapy**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

- **Mentorship**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

#### Session 4 (15:15-18:00)

- **Personalised Cancer Therapy**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

- **Mentorship**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

#### Session 5 (18:30-20:00)

- **Personalised Cancer Therapy**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

- **Mentorship**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**
  - **Spec.S**

---

**Note:** See pages 44 to 46 for colour and symbol details.

---

**ECCO 17 - ESMO 38 - ESTRO 32**

**Scientific Programme - Programme at a Glance**

---

**Saturday, 28 September 2013**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:45</td>
<td>Teaching Lecture</td>
</tr>
<tr>
<td>09:00-10:00</td>
<td>Scientific Symposium</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Ticketed Session</td>
</tr>
<tr>
<td>13:15-14:15</td>
<td>Abstracts</td>
</tr>
<tr>
<td>14:45-16:45</td>
<td>Satellite Sessions</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Debate</td>
</tr>
<tr>
<td>18:15-19:15</td>
<td>Round Table</td>
</tr>
</tbody>
</table>

**Sunday, 29 September 2013**

**Programme at a Glance**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:45</td>
<td>Teaching Lecture</td>
</tr>
<tr>
<td>09:00-10:00</td>
<td>Scientific Symposium</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Ticketed Session</td>
</tr>
<tr>
<td>13:15-14:15</td>
<td>Abstracts</td>
</tr>
<tr>
<td>14:45-16:45</td>
<td>Satellite Sessions</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Debate</td>
</tr>
<tr>
<td>18:15-19:15</td>
<td>Round Table</td>
</tr>
</tbody>
</table>

**Teaching Lecture**

- **08:00-08:45**: State of the ART in metastatic colorectal cancer
- **09:00-10:00**: Medication in metachronous colorectal cancer
- **11:30-12:00**: New insights in metastatic colorectal cancer
- **13:15-14:15**: New insights in advanced colorectal cancer
- **14:45-16:45**: Treatment of colorectal cancer

**Scientific Symposium**

- **09:00-10:00**: Proffered paper EUSOMA
- **11:30-12:15**: Proffered paper ESTRO
- **13:15-14:15**: Proffered paper EANM
- **14:45-16:45**: Proffered paper ESO
- **18:30-20:00**: Proffered paper SIOPE

**Ticketed Session**

- **09:00-10:00**: Society Symposium Sess. AES
- **11:15-12:00**: Ticketed Session

**Round Table**

- **17:00-18:00**: Debate
- **18:15-19:15**: Round Table

**Satellite Sessions**

- **08:00-08:45**: Proffered paper EUSOMA
- **09:00-10:00**: Proffered paper ESTRO
- **11:30-12:15**: Proffered paper EANM
- **13:15-14:15**: Proffered paper ESO
- **18:30-20:00**: Proffered paper SIOPE
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:45</td>
<td>T.L. Teaching Lecture: Breast Cancer: The way treatment in the light of the large database perspective</td>
</tr>
</tbody>
</table>
## Tuesday, 1 October 2013

### Programme at a Glance

**08:00-08:45**
- **Highlight session**
  - Practical tips and tricks with recently approved Molecular targeted Agents in NSCLC
  - International consensus guidelines for advanced breast cancer: An update
  - Incorporating Anti-vascular Therapy in Ovarian Cancer Management
  - Cancer Metastases
  - Modern management of penile Cancer
  - Current and future strategies in the treatment of operable oesophageal cancer
  - SBRT in Liver
  - The role of expert centers in the management of sarcomas
  - Cancer nursing training programme for community nurses
  - Mechanisms of underlying symptoms in cancer patients

**09:00-11:00**
- **Breast and Prostate cancers what can we learn from each other?**
- Lung Cancer in the non-smokers
- Metabolism and Cancer
- EAU Proffered paper session
- Innovative Molecular Imaging Strategies for Radiotherapy Individuation
- How to put evidence into daily nursing practice
- Geriatric assessment and their clinical applications
- Molecular profiling in Neuro-Oncology
- Diagnosis and treatment of oncological emergencies
- Enhancement of conventional oncological treatments with new technologies
- The Future of Paediatric Oncology in Europe

**11:30-12:30**
- Personalising adjuvant treatment in early breast cancer
- The pathology of lung cancer and its clinical implications
- 11:30-12:30 This house believes that super radical surgery is not the standard of care for advanced ovarian cancer
- 11:30-12:30 This house believes that chemoradiotherapy compensates for poor surgery in gastric cancer
- 11:30-12:30 This house believes that chemoradiotherapy compensates for poor surgery in gastric cancer
- 11:30-12:30 This house believes that chemoradiotherapy compensates for poor surgery in gastric cancer
- 11:30-12:30 Advanced Practitioners role in interdisciplin care: Where next?
- 11:30-12:30 Outcome issues for older patients
- 11:30-12:30 Repainting and tracking in ion beam therapy
- 11:30-12:30 This house believes that chemotherapy plays neither the standard of care in all CNS Lymphoma
- 11:30-12:30 This house believes that children with Sarcosomas and their families should be screened for family cancer syndrome mutations

**08:00-08:45**
- **International consensus guidelines for advanced breast cancer: An update**
- **Incorporating Anti-vascular Therapy in Ovarian Cancer Management**
- **Cancer Metastases**
- **Modern management of penile Cancer**
- **Current and future strategies in the treatment of operable oesophageal cancer**
- **SBRT in Liver**
- **The role of expert centers in the management of sarcomas**
- **Cancer nursing training programme for community nurses**
- **Mechanisms of underlying symptoms in cancer patients**

**09:00-11:00**
- **Breast and Prostate cancers what can we learn from each other?**
- **Lung Cancer in the non-smokers**
- **Metabolism and Cancer**
- **EAU Proffered paper session**
- **Innovative Molecular Imaging Strategies for Radiotherapy Individuation**
- **How to put evidence into daily nursing practice**
- **Geriatric assessment and their clinical applications**
- **Molecular profiling in Neuro-Oncology**
- **Diagnosis and treatment of oncological emergencies**
- **Enhancement of conventional oncological treatments with new technologies**
- **The Future of Paediatric Oncology in Europe**

**11:30-12:30**
- **Personalising adjuvant treatment in early breast cancer**
- **The pathology of lung cancer and its clinical implications**
- **11:30-12:30 This house believes that super radical surgery is not the standard of care for advanced ovarian cancer**
- **11:30-12:30 This house believes that chemoradiotherapy compensates for poor surgery in gastric cancer**
- **11:30-12:30 This house believes that chemoradiotherapy compensates for poor surgery in gastric cancer**
- **11:30-12:30 This house believes that chemoradiotherapy compensates for poor surgery in gastric cancer**
- **11:30-12:30 Advanced Practitioners role in interdisciplin care: Where next?**
- **11:30-12:30 Outcome issues for older patients**
- **11:30-12:30 Repainting and tracking in ion beam therapy**
- **11:30-12:30 This house believes that chemotherapy plays neither the standard of care in all CNS Lymphoma**
- **11:30-12:30 This house believes that children with Sarcosomas and their families should be screened for family cancer syndrome mutations**
General
Saturday 28 September 2013

Panel of Experts
Session: Multidisciplinary Tumour Board
* 8:00 - 9:00
Session details: To be announced

Opening Session: Biological Basis of Personalised Cancer Therapy
* 9:00 - 11:00
Welcome from Chairs

Stem cells in self-renewal
Speaker: H. Clevers (The Netherlands)
The genetic basis for future cancer therapies
Speaker: W.R. Sellers (USA)
Intratumour heterogeneity and personalised cancer medicine
Speaker: C. Swanton (United Kingdom)

Society Session: European Society of Surgical Oncology (ESSO)
* 11:15 - 13:15
Session details: To be announced

Presidential Session I: Best and Late Breaking Abstracts
* 13:45 - 15:45
ECCO Lifetime Achievement Award

Society Session: European Organisation for Research and Treatment of Cancer (EORTC) - Multidisciplinary Cancer Clinical Research: What are we up to in 2013?
* 16:00 - 18:00
Chair: R. Stupp (Switzerland)
Chair: F. Meunier (Belgium)
Chair: R. Stupp (Switzerland)

An analysis of the clinical cancer research landscape in 2013
Speaker: R. Stupp (Switzerland)

Challenges and opportunities to develop new drugs on the backbone of radiotherapy
Speaker: V. Gregoire (Belgium)

Challenges and opportunities for surgical trials, the role of quality assurance
Speaker: M. den Dulk (The Netherlands)

Clinically meaningful end-points: long term survival end-points versus early time to event based end-points
Speaker: B. Jonsson (Sweden)

Society Session: European Society for Paediatric Oncology (SIOP)
* 16:00 - 18:00
Session details: To be announced

Sunday 29 September 2013

Society Session: European Society of Breast Cancer Specialists (EUSOMA) - Ensuring Quality in Breast Care
* 9:00 - 11:00
Chair: R. Wilson (United Kingdom)
Chair: M. Gnant (Austria)
The Requirements of a Specialist Breast Center: Eusoma updated recommendations
Speaker: L. Marotti (Italy)
Auditing quality of care in a Breast Center
Speaker: P. Van Dam (Belgium)
Quality indicators in breast cancer: the Eusoma database experience
Speaker: A. Ponti (Italy)
European performance on Eusoma quality indicators
Speaker: R. Mansel (United Kingdom)
A parallel European objective: Guidelines for quality assurance in Breast Cancer Care and a voluntary accreditation scheme for Breast Cancer Services
Speaker: L. Marotti (Italy)
Discussion

Society Session: European Society for Therapeutic Radiology and Oncology (ESTRO)
* 9:00 - 11:00
Chair: V. Valentin (Italy)

Regaud Award Lecture
Award Lecturer: B. Glimelius (Sweden)
Honorary Member Award Lectures
Award Lecturer: R.K. Chhem (Austria)
Award Lecturer: R. Hermans (Belgium)
Award Lecturer: B. Minsky (USA)
Award Lecturer: C.J.H. van de Velde (The Netherlands)
Company Award Lectures
Accuracy
Varian

Society Session: European Society for Nuclear Medicine (EANM)
* 9:00 - 11:00
Session details: To be announced

Society Session: European School of Oncology (ESO) - The Importance of Management Skills in Running Oncology Services
* 9:00 - 11:00
Session details: To be announced

Society Session: European Society of Oncology Pharmacy (ESOP)
* 9:00 - 11:00
Session details: To be announced

Keynote Lecture: Mouse Hospital and the Co-Clinical Trial Project
* 11:30 - 12:15
Speaker: P.P. Pandolfi (USA)

Presidential Session II: Best and Late Breaking Abstracts
* 12:30 - 14:30
Chair: M. Piccart (Belgium)
ECCO Pezcoller Award
ESMO Hamilton-Fairly Award
Scientific Symposium: Joint ECCO / ASCO Session  
* 14:45 - 16:45  
Session details: To be announced

Scientific Symposium: ES MO Clinical Recommendation Session  
* 14:45 - 16:45  
Session details: To be announced

Society Session: European Society of Gynaecological Oncology (ESGO)  
* 14:45 - 16:45  
Chair: A. Casado (Spain)  
Chair: A. Van der Zee (The Netherlands)  
Role of centralisation in outcome of gynecogical cancer treatment and organisation of cancer services  
Speaker: N. Reed (United Kingdom)  
Risk factors and prevention of gynecological cancer (Healthy life style, diet and exercise as factors in suvervorship: obesity and alcohol and endometrial cancer)  
Speaker: A. Nordin (United Kingdom)  
Cancer in pregnancy  
Speaker: F. Amant (Belgium)  
Psycho-oncology  
Speaker: V. Kesic (Serbia)  
ESGO/ENGT scientific portfolio  
Speaker: I. Vergote (Belgium)  
Questions & Answers

Society Session: European Association for Cancer Research (EACR)  
* 14:45 - 16:45  
Session details: To be announced

Keynote Lecture:  
* 11:30 - 12:15  
Speaker: M. Baumann (Germany)

Presidental Session III: Best and Late Breaking Abstracts  
* 12:30 - 14:30

ECCO Clinical Research Award

Society Session: European Society for Medical Oncology (ESMO) - Increased Fragmentation of Solid Tumours  
* 14:45 - 16:45  
Chair: M. Piccart (Belgium)  
Chair: J.S. de Bono (United Kingdom)  
Molecular screening and patient selection for phaseI/II trials  
Speaker: F. Bedard (Canada)  
Implications for patient care  
Speaker: J. De Grève (Belgium)  
Discussion  
ESMO Award  
ESMO Lifetime Achievement Award and lecture  
ESMO Fellowships  
ESMO 2012 Best Examination

TUESDAY 1 OCTOBER 2013

Scientific Symposium: Breast and Prostate Cancers: What we can Learn From Each Other?  
* 9:00 - 11:00  
Chair: F. Cardoso (Portugal)  
Chair: J.S. de Bono (United Kingdom)  
Introduction  
Speaker: F. Cardoso (Portugal)  
Role of micro-environment in resistance to endocrine therapies  
Speaker: M. Dowsett (United Kingdom)  
Androgen-receptor: a two-edge sword?  
Speaker: W. Tilley (Australia)  
Micro-environment and bone metastases  
Speaker: R.E. Coleman (United Kingdom)  
The role of epithelial-mesenquimal transition (EMT) in the lost of AR/ER expression  
Speaker: H. Wu (USA)  
Concluding Remarks  
Speaker: J.S. de Bono (United Kingdom)  

Award Presentation
BASIC SCIENCE

SATURDAY 28 SEPTEMBER 2013

Scientific Symposium: Targeting the Microenvironment
11:15 - 13:15
Chair: S.A. Eccles (United Kingdom)
Chair: R. Kalluri (USA)
Introduction
Speaker: S.A. Eccles (United Kingdom)
The roles of LOX
Speaker: J. Erler (Denmark)
Cancer stem cells and niches
Speaker: I. Malanchi (United Kingdom)
Inflammation
Speaker: M. Karin (USA)
Stromal factors and metastasis
Speaker: R. Kalluri (USA)
Concluding remarks
Speaker: R. Kalluri (USA)

Scientific Symposium: Metabolism and Cancer
9:00 - 11:00
Chair: D. Peeper (The Netherlands)
Chair: C. Simon (USA)
Introduction
Speaker: D. Peeper (The Netherlands)
AMP kinase, metformin and cancer
Speaker: G. Hardie (United Kingdom)
Tumour metabolism
Speaker: C. Simon (USA)
Targeting the PI3K pathway in cancer
Speaker: P. Workman (United Kingdom)
p53 and metabolism
Speaker: D. Peeper (The Netherlands)
Concluding Remarks
Speaker: C. Simon (USA)

Monday 30 September 2013

Special Session: Molecular Imaging
17:00 - 18:00
Chair: K. Brindle (United Kingdom)
MOBILE (Mapping of oxygen by imaging lipids relaxation enhancement) - New approach to imaging hypoxia by MR
Speaker: B. Gallez (Belgium)
Preclinical and clinical optical imaging
Speaker: G. van Dam (The Netherlands)
PET/MR imaging
Speaker: A. Beer (Germany)
Discussion and Roundup

Tuesday 1 October 2013

Teaching Lecture: Cancer Metastases
8:00 - 8:45
Speaker: M.J. Hendrix (USA)

Scientific Symposium: Autophagy in Cancer and Cancer Therapy
11:30 - 12:30
Chair: J. Pouyssegur (France)
Autophagy and cell death
Speaker: A. Kimchi (Israel)
The importance of autophagy in cancer
Speaker: G. Kroemer (France)
Fundamental mechanisms in autophagy
Speaker: S. Tooze (United Kingdom)
Discussion and Roundup

Sunday 29 September 2013

Teaching Lecture: Genetic Variation and Cancer- What Next?
8:00 - 8:45
Speaker: N. Rahman (United Kingdom)

BREAST CANCER- EARLY AND ADVANCED DISEASE

Saturday 28 September 2013

Teaching Lecture: Bone Metastasis: Causes, Consequences and Therapeutic Opportunities
8:00 - 8:45
Speaker: J. Cortés (Spain)
**Sunday 29 September 2013**

**Teaching Lecture: State of the art in Neoadjuvant Therapy of Breast Cancer**
- 8:00 - 8:45

Speaker: G. von Minckwitz (Germany)

**Scientific Symposium: Technical and Biological Developments in Breast Radiotherapy**
- 14:45 - 16:45

Chair: A. Fourquet (France)
Chair: R. Orecchia (Italy)

**Introduction**
Speaker: A. Fourquet (France)

**Impact of radiotherapy on loco-regional control**
Speaker: I. Kunkler (United Kingdom)

**Image-guided radiotherapy**
Speaker: P. Poortmans (The Netherlands)

**The long and short of radiation fractionation**
Speaker: J. Yarnold (United Kingdom)

**Intra-operative radiotherapy A (ELIOT)**
Speaker: R. Orecchia (Italy)

**Intra-operative radiotherapy B (TARGIT)**
Speaker: F. Wenz (Germany)

**Concluding remarks**
Speaker: R. Orecchia (Italy)

**Debate: This House Believes That Axillary Dissection Should be Avoided in Patients With Positive Sentinel Node**
- 17:00 - 18:00

Moderator: R. Wilson (United Kingdom)

Speaker in favour: E.J.T. Rutgers (The Netherlands)

Speaker against: M. Leidenius (Finland)

Second in favour: N. Bundred (United Kingdom)

Second against: M. Gnant (Austria)

**Monday 30 September 2013**

**Teaching Lecture: Best Management of Locally Advanced Inoperable Breast Cancer**
- 8:00 - 8:45

Speaker: G. Curigliano (Italy)

**Scientific Symposium: Metastatic Breast Cancer: From Biology to Therapeutic Strategies**
- 9:00 - 11:00

Chair: M. Piccart (Belgium)
Chair: L. Gianni (Italy)

**Introduction**
Speaker: M. Piccart (Belgium)

**Dealing with tumour heterogeneity: the exception or the rule?**
Speaker: M. Piccart (Belgium)

**How to best assess response: new imaging techniques**
Speaker: E.G.E. de Vries (The Netherlands)

**How to best assess response: blood-based tests**
Speaker: J. Pierga (France)

**Personalised drug discovery: an academic experience**
Speaker: F. Andre (France)

**Concluding Remarks**
Speaker: L. Gianni (Italy)

**Tuesday 1 October 2013**

**Teaching Lecture: International Consensus Guidelines for Advanced Breast Cancer: An Update**
- 8:00 - 8:45

Speaker: F. Cardoso (Portugal)

**Special Session: Personalising Adjuvant Treatment in Early Breast Cancer**
- 11:30 - 12:30

Chair: M. Piccart (Belgium)

**The pathologists’ contribution to personalised treatment**
Speaker: J. Res-Filho (United Kingdom)

**Is it safe to omit systemic therapy in small Her2+ node negative breast cancers?**
Speaker: E. Winer (USA)

**Questions and answers with final vote**

**CANCER IN THE OLDER PATIENT**

**Monday 30 September 2013**

**Teaching Lecture: The Best Treatment for Older Patients With Breast Cancer**
- 8:00 - 8:45

Speaker: L. Biganzoli (Italy)

**Tuesday 1 October 2013**

**Scientific Symposium: Geriatric Assessment and Their Clinical Applications**
- 9:00 - 11:00

Chair: C. Terret (France)
Chair: B. Van Leeuwen (The Netherlands)

**Definition of ageing and functional decline**
Speaker: S.R. Kristjansson (Norway)

**Comorbidities**
Speaker: U. Wedding (Germany)

**Nutrition**
Speaker: P. Soubeyran (France)

**Is frailty assessment effective?**
Speaker: H. Wildiers (Belgium)

**Concluding Remarks**
Speaker: B. Van Leeuwen (The Netherlands)

**Special Session: Outcome Issues for the Older Patient**
- 11:30 - 12:30

Chair: E. Brain (France)
Which outcomes for older cancer patients
Speaker: M. Janssen-Heijnen (The Netherlands)

New targeted outcomes for colorectal cancer in older patients
Speaker: G. Liefers (The Netherlands)

Discussion and Roundup

CENTRAL NERVOUS SYSTEM

Monday 30 September 2013

Teaching Lecture: The Way to Improve Outcome in Newly-diagnosed Glioblastoma
8:00 - 8:45
Speaker: R. Stupp (Switzerland)

Special Session: Current and Future Approaches for Recurrent Glioblastoma
17:00 - 18:00
Chair: R. Stupp (Switzerland)

Does surgery at relapse impact survival?
Speaker: J. Tonn (Germany)

Role of focal therapy in an infiltrative disease
Speaker: B. Baumert (The Netherlands)

What is the best option for recurrent glioblastoma in 2013 and 2023?
Speaker: A. Brandes (Italy)

Discussion and Roundup

Tuesday 1 October 2013

Scientific Symposium: Molecular Profiling in Neuro-Oncology
9:00 - 11:00
Chair: M. Hegi (Switzerland)
Chair: S. Niclou (Luxembourg)

Introduction
Speaker: M. Hegi (Switzerland)

Glioblastomas
Speaker: W. Wick (Germany)

Anaplastic gliomas
Speaker: M.J. van den Bent (The Netherlands)

Brain metastases
Speaker: R. Soffietti (Italy)

Medulloblastomas
Speaker: S. Pfister (Germany)

Concluding Remarks
Speaker: S. Niclou (Luxembourg)

Debate: This House Believes That Radiotherapy Plays no Role in the Treatment of Primary CNS Lymphoma
11:30 - 12:30
Moderator: R. Soffietti (Italy)
Speaker in favour: M. Weller (Switzerland)
Speaker against: A.J. Ferreri (Italy)
Seconder in favour: M. Brada (United Kingdom)
Seconder against: E. Moyal (France)

Questions and answers with final vote

DIAGNOSTIC / BIOMARKERS

Monday 30 September 2013

Scientific Symposium: How Next Generation Sequencing is Changing Therapeutic Decision Making
9:00 - 11:00
Chair: N. Harbeck (Germany)
Chair: M. Van de Vijver (The Netherlands)

Introduction
Speaker: N. Harbeck (Germany)

Next generation sequencing: Basic principles and applications in the biomarker arena
Speaker: P. Campbell (United Kingdom)

Massively parallel sequencing analysis of clinical samples: Challenges and opportunities
Speaker: M.F. Berger (USA)

The role of massively parallel sequencing for the identification of predictors of therapy response
Speaker: M. Ellis (USA)

The impact of massively parallel sequencing on the classification and prediction of haematological malignancies
Speaker: T. Hafenlocher (Germany)

Concluding Remarks
Speaker: M. Van de Vijver (The Netherlands)

Debate: This House Believes That the Assessment of Biomarkers on a Single Biopsy of the Primary Tumour is Sufficient to Determine Systemic Therapy in Metastatic Disease
17:00 - 18:00
Moderator: J. Reis-Filho (United Kingdom)
Speaker in favour: M. Ladanyi (USA)
Speaker against: P. Campbell (United Kingdom)
Seconder in favour: L. Pusztai (USA)
Seconder against: M. Ellis (USA)

Questions and answers with final vote

DRUG DEVELOPMENT

Sunday 29 September 2013

Teaching Lecture: Pharmacogenetics in the Clinic
8:00 - 8:45
Speaker: H. Guchelaar (The Netherlands)

Special Session: Epigenetics in Cancer
13:15 - 14:15
Chair: C. Sessa (Switzerland)

Epigenetic therapies in haematologic and solid malignancies
Speaker: M. Esteller (Spain)

DNA methyltransferase inhibitors
Speaker: J.P. Issa (USA)

How to overcome resistance to HDAC inhibitors?
Speaker: S. Bates (USA)

Discussion and Roundup

Scientific Symposium: Optimal use of Targeted Kinase Inhibitors (TKIs)
14:45 - 16:45
Chair: A.K. Larsen (France)
Chair: J. Baselga (USA)

Introduction
Speaker: A.K. Larsen (France)
How to combine TKIs: pharmacological optimisation
Speaker: A.K. Larsen (France)

Role of genomic sequencing in therapeutic decision making with TKIs
Speaker: E. Voest (The Netherlands)

What is best: multi-targeted or single TKIs?
Speaker: J. Baselga (USA)

Clinical development of TKIs: learning from our mistakes
Speaker: S. Sleijfer (The Netherlands)

Concluding Remarks
Speaker: J. Baselga (USA)

Debate: This House Believes That Progression free Survival is a Valid endpoint in Drug Development
Moderator: P. Schöffski (Belgium)

Speaker in favour: C. Twelves (United Kingdom)
Speaker against: I.F. Tannock (Canada)
Seconder in favour: D. Sargent (USA)
Seconder against: M. Parmar (United Kingdom)

Questions and answers with final vote

EDUCATION

Saturday 28 September 2013

Educational Symposium: Optimal Approach in Early Breast Cancer
Chair: L. Wyld (United Kingdom)

Optimal surgical approach
Speaker: A.E. Giuliano (USA)

Adjuvant and neoadjuvant treatment
Speaker: F. Cardoso (Portugal)

The role of the pathologist in decision making
Speaker: A.P. Dei Tos (Italy)

Modern Radiation Therapy
Speaker: P. Poortmans (The Netherlands)

Monday 30 September 2013

Interactive Session With Patient Cases: Patient With Colorectal Liver Metastasis
Chair: C.J.A. Punt (The Netherlands)

Optimal staging/imaging
Speaker: R.G.H. Beets-Tan (The Netherlands)

Neoadjuvant therapy before surgical treatment
Speaker: R. Glynne-Jones (United Kingdom)

Optimal surgery
Speaker: H. Rutten (The Netherlands)

Adjuvant chemotherapy
Speaker: B. Glimelius (Sweden)

Sunday 29 September 2013

Educational Symposium: Optimal Approach for Localised Rectal Cancer
Chair: C.J.A. Punt (The Netherlands)

Targeted therapy in melanoma: the role of B Raf, Ras and kit mutations
Speaker: R. Dummer (Switzerland)

Immunotherapy in melanoma
Speaker: J.B.A.G. Haanen (The Netherlands)

Adjuvant therapy
Speaker: A.M.M. Eggermont (France)

Interactive Workshop: How to communicate with High-risk Population(s)
Chair: A. Roshanai (Sweden)

Coordinator: A. Roshanai (Sweden)

Coordinator: P. Leonard (United Kingdom)

Educational Symposium: Optimal Approach for Upfront Resectable NSCLC
Chair: J. Van Meerbeeck (Belgium)

Surgery & TNM
Speaker: C. Le Pechoux (France)

Adjuvant radiotherapy
Speaker: C. Le Pechoux (France)

Adjuvant chemotherapy
Speaker: J. Douillard (France)

Pathology prognostic value of different groups
Speaker: K. Kerr (United Kingdom)

New TNM staging
Speaker: J. Van Meerbeeck (Belgium)
Educational Symposium: Optimal Approach for Renal Cancer
14:45 - 16:45
Chair: C.N. Sternberg (Italy)
Individualising treatment choices in a crowded treatment algorithm
Speaker: J. Larkin (United Kingdom)
Does a reasonable treatment approach beyond 2nd-line exist?
Speaker: B. Escudier (France)
Understanding and managing VEGFR-inhibitors toxicities
Speaker: M. Schmidinger (Austria)
Integrating metastasectomy and stereotactic radiosurgery in the treatment of mRCC
Speaker: A. Bex (The Netherlands)

Educational Symposium: Mood Disorders in Cancer Patients
14:45 - 16:45
Chair: To be announced
Depression
Speaker: S. Dauchy (France)
Anxiety and sleep disturbance
Speaker: To be announced
Cognitive dysfunctions
Speaker: S. Schagen (The Netherlands)
Drug-associated delirium
Speaker: To be announced

Interactive Workshop: Dealing with Angry Patients and Families as a Care Provider
17:00 - 18:00
Coordinator: L. Fallowfield (United Kingdom)
Coordinator: A. Mehnert (Germany)

Tuesday 1 October 2013
Educational Symposium: Lung Cancer in Non-smokers
9:00 - 11:00
Chair: R. Stahel (Switzerland)
Epidemiology
Speaker: To be announced
Prevention – Passive smoking and pregnancy
Speaker: To be announced
Politics
Speaker: C. Hill (France)
Genetics
Speaker: R. Govindan (USA)

Educational Symposium: Lung Cancer in Non-smokers
9:00 - 11:00
Chair: R. Stahel (Switzerland)
Epidemiology
Speaker: To be announced
Prevention – Passive smoking and pregnancy
Speaker: To be announced
Politics
Speaker: C. Hill (France)
Genetics
Speaker: R. Govindan (USA)

Aspirin and GI cancer incidence
Speaker: P.M. Rothwell (United Kingdom)
Aspirin and other cancers
Speaker: C. Bosetti (Italy)
Aspirin in prognosis and pharmacogenetics
Speaker: C. Ulrich (Germany)
Discussion and Roundup

Monday 30 September 2013
Scientific Symposium: Lifestyle, Exercise and Vitamins
14:45 - 15:45
Chair: Z. Herceg (France)
Chair: E. Riboli (United Kingdom)
Introduction
Speaker: Z. Herceg (France)
Cervical cancer screening in light of HPV testing and immunisations
Speaker: E. Franco (Canada)
New opportunities and challenges in colorectal cancer screening – FIT vs FOBT vs sigmoidoscopy
Speaker: N. Segnan (Italy)
Should all men have PSA Screening?
Speaker: J. Cuzick (United Kingdom)
Breast cancer screening
Speaker: D.A. Cameron (United Kingdom)
The cost-effectiveness of cancer screening
Speaker: H.J. de Koning (The Netherlands)
Concluding Remarks
Speaker: E. Riboli (United Kingdom)

Concluding Remarks
Speaker: D. Elias (France)

Saturday 29 September 2013
Special Session: Aspirin – A Wonder Drug in the Fight Against Cancer?
13:15 - 14:15
Chair: C. Ulrich (Germany)
Aspirin and GI cancer incidence
Speaker: P.M. Rothwell (United Kingdom)
Aspirin and other cancers
Speaker: C. Bosetti (Italy)
Aspirin in prognosis and pharmacogenetics
Speaker: C. Ulrich (Germany)

Saturday 28 September 2013
Scientific Symposium: Cancer Screening – Redefining the Modality of Screening
16:00 - 18:00
Chair: J. Cuzick (United Kingdom)
Chair: D.A. Cameron (United Kingdom)
Introduction
Speaker: J. Cuzick (United Kingdom)
Cervical cancer screening in light of HPV testing and immunisations
Speaker: E. Franco (Canada)
New opportunities and challenges in colorectal cancer screening – FIT vs FOBT vs sigmoidoscopy
Speaker: N. Segnan (Italy)
Should all men have PSA Screening?
Speaker: J. Cuzick (United Kingdom)
Breast cancer screening
Speaker: D.A. Cameron (United Kingdom)
The cost-effectiveness of cancer screening
Speaker: H.J. de Koning (The Netherlands)
Concluding Remarks
Speaker: D.A. Cameron (United Kingdom)

Sunday 29 September 2013
Special Session: Aspirin – A Wonder Drug in the Fight Against Cancer?
13:15 - 14:15
Chair: C. Ulrich (Germany)
Aspirin and GI cancer incidence
Speaker: P.M. Rothwell (United Kingdom)
Aspirin and other cancers
Speaker: C. Bosetti (Italy)
Aspirin in prognosis and pharmacogenetics
Speaker: C. Ulrich (Germany)
Discussion and Roundup

GASTROINTESTINAL MALIGNANCIES - COLORECTAL CANCER

Saturday 28 September 2013
Teaching Lecture: Role of aggressive surgery for peritoneal metastases
8:00 - 8:45
Speaker: D. Elias (France)
Sunday 29 September 2013

Teaching Lecture: Radiotherapy for Rectal Cancer: Short Course vs Long Course - When and How?

8:00 - 8:45

Speaker: D. Sebag-Montefiore (United Kingdom)

Debate: This House Believes That the Primary Tumour Should be Removed in Synchronous Metastatic Colorectal Cancer

17:00 - 18:00

Moderator: R. Glynne-Jones (United Kingdom)

Speaker in favour: T.J.M. Ruers (The Netherlands)

Speaker against: P. Rougier (France)

Seconder in favour: M. Koopman (The Netherlands)

Seconder against: C. Marijnen (The Netherlands)

Questions and answers with final vote

Monday 30 September 2013

Scientific Symposium: Personalised Treatment in Colorectal Cancer

9:00 - 11:00

Chair: E. Van Cutsem (Belgium)

Chair: T.S. Maughan (United Kingdom)

Introduction

Speaker: E. Van Cutsem (Belgium)

Are predictive/prognostic biomarkers/platforms ready to be placed in adjuvant treatments?

Speaker: A. Roth (Switzerland)

Selecting for maintenance of stop-and-go strategy in mCRC

Speaker: A. de Gramont (France)

Selecting for anti-EGFR inhibitors in CRC: KRAS and beyond?

Speaker: E. Van Cutsem (Belgium)

Do we have a light for predictive biomarkers with angiogenesis inhibitors or are we still lost in translation?

Speaker: D. Lambrechts (Belgium)

Concluding Remarks

Speaker: T.S. Maughan (United Kingdom)

Scientific Symposium: Molecular Classification of CRC: Ready for Prime Time?

14:45 - 16:45

Chair: W. Steward (United Kingdom)

Chair: F. Ciardiello (Italy)

Introduction

Speaker: W. Steward (United Kingdom)

Pitfalls of and opportunities for molecular characterisation in CRC

Speaker: P. Quirke (United Kingdom)

Strategies for K-RAS mutated

Speaker: A. Bardelli (Italy)

Strategies for B-RAF mutated

Speaker: R. Bernards (The Netherlands)

Relevance of non K-RAS mutations for new drug selection

Speaker: S. Tejpar (Belgium)

Concluding Remarks

Speaker: F. Ciardiello (Italy)

Special Session: Risks and Benefits of Organ Preservation in Treating Rectal Cancer

17:00 - 18:00

Chair: H. Rutten (The Netherlands)

Selecting patients suitable for organ preservation through imaging

Speaker: G. Brown (United Kingdom)

Tailoring neoadjuvant radio-chemo-therapy treatment for organ preservation

Speaker: G. Lammering (The Netherlands)

The oncological and functional risks of the organ preservation experimental treatment approach

Speaker: C. Coco Martins (Portugal)

Discussion and Roundup

Tuesday 1 October 2013

Teaching Lecture: Current and Future Strategies in the Treatment of Operable Oesophageal Cancer

8:00 - 8:45

Speaker: A. van der Gaast (The Netherlands)

Debate: This House Believes That Chemoradiotherapy Compensates for Poor Surgery in Gastric Cancer

11:30 - 12:30

Moderator: M. Stahl (Germany)

Speaker in favour: C. Schuhmacher (Germany)

Speaker against: M. Verheij (The Netherlands)

Seconder in favour: D. Cunningham (United Kingdom)

Seconder against: F. Lordick (Germany)

Questions and answers with final vote

GASTROINTESTINAL MALIGNANCIES - NONCOLORECTAL CANCER

Monday 30 September 2013

Scientific Symposium: Therapeutic Procedures in Liver Metastases: Conventional and Future

9:00 - 11:00

Chair: L.A. Dauxson (Canada)

Chair: G. ter Haar (United Kingdom)

Introduction

Speaker: L.A. Dauxson (Canada)

SBRT for which patients?

Speaker: L.A. Dauxson (Canada)

RFA for which patients?

Speaker: A. Veltri (Italy)

Radioembolization for which patients?

Speaker: A. Hendlisz (Belgium)

HIFU for which patients?

Speaker: G. ter Haar (United Kingdom)

Concluding remarks

Speaker: G. ter Haar (United Kingdom)

Special Session: Controversies in Gallbladder Cancer

13:15 - 14:15

Chair: J. Primrose (United Kingdom)

When should we worry about gallbladder polyps?

Speaker: S.W. Fenwick (United Kingdom)

Management of Stage T1B gallbladder cancer discovered after laparoscopic cholecystectomy

Speaker: Y. Fong (USA)

Management of Stage 3 gallbladder cancer

Speaker: T. Gruenberger (Austria)

Discussion and Roundup
Sunday 29 September 2013

Teaching Lecture: Survivorship in Testis
8:00 - 8:45
Speaker: G. Daugaard (Denmark)

Special Session: Management of Bladder Cancer
13:15 - 14:15
Chair: M. De Santis (Austria)
Surgical status of lymphadenectomy
Speaker: A. Stenzl (Germany)
Is organ preservation viable?
Speaker: N.D. James (United Kingdom)
Biomarkers in bladder cancer
Speaker: J. Bellmunt (Spain)
Discussion and Roundup

Scientific Symposium: New Challenges in Metastatic Renal Cancer Cells: Identifying What is Worth Pursuing
14:45 - 16:45
Chair: M. Schmidinger (Austria)
Chair: C.N. Sternberg (Italy)
Introduction
Speaker: M. Schmidinger (Austria)
Identifying biomarkers in RCC
Speaker: T. Eisen (United Kingdom)
Immune therapy in renal cancer: not such an ugly duckling?
Speaker: P. Mulders (The Netherlands)
The mechanism of resistance to targeted therapy
Speaker: T. Poulas (United Kingdom)
The role of novel and established imaging modalities in predicting outcomes in clear cell renal cancer
Speaker: L. Fournier (France)
Concluding Remarks
Speaker: C.N. Sternberg (Italy)

Debate: This House Believes There is no Need for More VEGFR TKIS to Treat Renal Cancer Cells
17:00 - 18:00
Moderator: M. Schmidinger (Austria)
Speaker in favour: T. Eisen (United Kingdom)
Second in favour: C. Porta (Italy)
Speaker against: E. Calvo (Spain)
Second against: B. Escudier (France)
Questions and answers with final vote

Tuesday 1 October 2013

Teaching Lecture: Modern Management of Penile Cancer
8:00 - 8:45
Speaker: V. Khoo (United Kingdom)

Scientific Symposium: Castration Resistant Prostate Cancer Targeting Cancer Cells, Microenvironment and Stem Cells
16:00 - 18:00
Chair: K. Fizazi (France)
Chair: F. Saad (Canada)
Introduction
Speaker: K. Fizazi (France)
Targeting stem cells
Speaker: K.L. Blanchard (China)
Targeting immune system
Speaker: W. Gerritsen (The Netherlands)
Targeting bone microenvironment
Speaker: F. Saad (Canada)
Cancer cells in general and specific pathways
Speaker: J.S. de Bono (United Kingdom)
Concluding Remarks
Speaker: F. Saad (Canada)

Monday 30 September 2013

Debate: This House Believes low Risk Prostate Cancer Should not be Treated as Cancer
17:00 - 18:00
Moderator: P. Abrahamsson (Sweden)
Low risk
Speaker in favour: M. Wirth (Germany)
Active risk
Speaker against: A. Heidenreich (Germany)
Low risk
Seconder in favour: F. Algaba (Spain)
Active risk
Seconder against: A. Bossi (France)
Questions and answers with final vote

Tuesday 1 October 2013

Special Session: Castration-resistant Prostate Cancer: New Therapies
11:30 - 12:30
Chair: H. Scher (USA)
Molecular pathways of castration resistance in prostate cancer
Speaker: J. Scholten (The Netherlands)
Androgen receptor targeted approaches for managing CRPC (MDV3100, Abiraterone Taki-700, etc.)
Speaker: H. Scher (USA)

Non-AR targeted approaches for managing CRPC (bone targeted agents, second line chemotherapy, cabozantinib etc)
Speaker: M. Smith (USA)

Discussion and Roundup

GYNAECOLOGICAL CANCER

MONDAY 30 SEPTEMBER 2013

Teaching Lecture: How to Integrate Sentinel Nodes in Therapy?
- 8:00 - 8:45
Sentinal nodes in vulval and cervical cancer
Speaker: A. Van der Zee (The Netherlands)

Sentinal nodes in endometrial cancer
Speaker: M. Ballester (France)

Scientific Symposium: Potential Novel Targets in Gynaecological Cancer
- 9:00 - 11:00
Chair: S.B. Kaye (United Kingdom)
Chair: A. Casado (Spain)

Introduction
Speaker: S.B. Kaye (United Kingdom)

Novel membrane receptors (Folate, IGFFR, EGFR)
Speaker: A. Leary (France)

Novel agents in overcoming drug resistance
Speaker: A. Reyners (The Netherlands)

PARP inhibitors
Speaker: S. Banerjee (United Kingdom)

AKT, mTOR, PI3 kinase
Speaker: A. Oza (Canada)

Concluding Remarks
Speaker: A. Casado (Spain)

Special Session: Improving Therapy for Locally Advanced Cervical Cancer
- 13:15 - 14:15
Chair: C. Creutzberg (The Netherlands)

Image-guided adaptive brachytherapy
Speaker: P Petric (Slovenia)

Optimal management of nodal disease
Speaker: A. Taylor (United Kingdom)

Rationale and trials of adjuvant therapy after chemoradiation
Speaker: D. O’Donnell (Ireland)

Discussion and Roundup

TUESDAY 1 OCTOBER 2013

Teaching Lecture: Incorporating Anti-vascular Therapy in Ovarian Cancer Management
- 8:00 - 8:45
Speaker: A. Clamp (United Kingdom)

Debate: This House Believes that Supra-radical Surgery is not the Standard of Care for Advanced Ovarian Cancer
- 11:30 - 12:30
Moderator: R. Rouzier (France)
Speaker in favour: S. Kehoe (United Kingdom)
Speaker against: E. Leblanc (France)
Second in favour: G. Rustin (United Kingdom)
Second against: J. Sehouli (Germany)

Questions and answers with final vote

HAEMATOLOGICAL MALIGNANCIES AND MYELOMA

SATURDAY 28 SEPTEMBER 2013

Revealing new Lymphoma Targets Through Sequencing Projects
- 8:00 - 8:45
Speaker: G. Lenz (Germany)

Special Session: Treatment of Chronic Lymphocytic Leukaemia
- 14:15 - 15:15
Chair: S. Stilgenbauer (Germany)

Genetics of chronic lymphocytic leukemia
Speaker: P. Chia (Italy)

First-line treatment of chronic lymphocytic leukaemia
Speaker: P. Hillmen (United Kingdom)

Treatment of relapsed chronic lymphocytic leukaemia
Speaker: S. Stilgenbauer (Germany)

Discussion and Roundup

Scientific Symposium: Dissecting Total Therapy for Multiple Myeloma
- 16:00 - 18:00
Chair: J.-L. Harousseau (France)
Chair: V. Montefusco (Italy)

Introduction
Speaker: J.-L. Harousseau (France)

First-line treatment in elderly patients
Speaker: A. Palumbo (Italy)

First-line treatment in young patients
Speaker: J.F. San Miguel (Spain)

Defining and maintaining response
Speaker: M. Attali (France)

New drugs
Speaker: M.A. Dimopoulos (Greece)

Concluding Remarks
Speaker: V. Montefusco (Italy)

SUNDAY 29 SEPTEMBER 2013

Scientific Symposium: Care of Special Lymphomas - Challenges in the Clinical Routine
- 9:00 - 11:00
Chair: M.A. Dimopoulos (Greece)
Chair: C. Thieblemont (France)

Introduction
Speaker: M.A. Dimopoulos (Greece)

M. Waldenstroem
Speaker: M.A. Dimopoulos (Greece)

MALT lymphoma
Speaker: C. Thieblemont (France)

CNS lymphoma
Speaker: A.J. Ferreri (Italy)

Post-transplantation lymphoproliferative disease
Speaker: R. Trappe (Germany)

Concluding Remarks
Speaker: C. Thieblemont (France)
Debate: This House Believes That Autologous Stem Cell Transplantation is the First-line Treatment for High Risk Diffused Large Cell Lymphoma  
17:00 - 18:00

Moderator: M.H. Dreyling (Germany)  
Speaker in favour: U. Vitolo (Italy)  
Speaker against: N. Schmitz (Germany)  
Seconder in favour: H. Tilly (France)  
Seconder against: P. Johnson (United Kingdom)

Questions and answers with final vote

HEAD AND NECK CANCER

Saturdays 28 September 2013

Teaching Lecture: Current Role of HPV in Head and Neck Oncology  
8:00 - 8:45
Speaker: P. Lassen (Denmark)

Scientific Symposium: Induction Chemotherapy in the Treatment of Squamous Cell Head and Neck Cancer  
11:15 - 13:15
Chair: H.E. Eckel (Austria)  
Chair: C. Grau (Denmark)

Introduction
Speaker: H.E. Eckel (Austria)

The current status of induction chemotherapy in head and neck squamous cell carcinoma  
Speaker: L. Licitra (Italy)

Assessment of response after induction chemotherapy as the basis of subsequent local therapy  
Speaker: R. de Bree (The Netherlands)

Role of induction chemotherapy in the nasopharyngeal carcinoma  
Speaker: A.W. Lee (Hong Kong)

Function-sparing radiation in curable head and neck cancer  
Speaker: H. Langendijk (The Netherlands)

Concluding Remarks
Speaker: C. Grau (Denmark)

Sundays 29 September 2013

Scientific Symposium: Imaging to Support Drug Development  
16:00 - 18:00
Chair: W.J.G. Oyen (The Netherlands)  
Chair: E.G.E. de Vries (The Netherlands)

Introduction
Speaker: W.J.G. Oyen (The Netherlands)

Use of advanced imaging in drug development: the industry perspective  
Speaker: B. Fine (USA)

Minimising lymphoma treatment using PET  
Speaker: M. Hutchings (Denmark)

Optimising treatment schemes using PET  
Speaker: W. Weber (Germany)

Molecular imaging using radiolabel drugs  
Speaker: E.F. Smit (The Netherlands)

Concluding Remarks
Speaker: E.G.E. de Vries (The Netherlands)

INDUSTRY

Sessions: To be announced
LUNG CANCER – METASTATIC AND LOCALISED/SYSTEMIC

SATURDAY 28 SEPTEMBER 2013

Teaching Lecture: Novel Therapy Treatment Options in Early Stage NSCLC
- 8:00 - 8:45
Speaker: J. Van Meerbeeck (Belgium)

Scientific Symposium: Therapeutic Implications for New Targets in Lung Cancer
- 16:00 - 18:00
Chair: P. Baas (The Netherlands)
Chair: A. Adjei (USA)

Introduction
Speaker: P. Baas (The Netherlands)
Immune-checkpoints (PD1, PDL1)
Speaker: A. Adjei (USA)
PI3K-AKT-mTOR
Presenter: B. Besse (France)
Ras-Raf-MEK Pathway
Speaker: J.H.M. Schellens (The Netherlands)
ALX and HSP90
Speaker: F. Blackhall (United Kingdom)

Concluding Remarks
Speaker: A. Adjei (USA)

SUNDAY 29 SEPTEMBER 2013

Special Session: Concurrent Chemo-Radiotherapy Prediction of Outcome and Toxicity
- 17:00 - 18:00
Chair: D. Hollywood (Ireland)

Predicting survival
Speaker: C. Oberjeir (The Netherlands)

Predicting oesophageal and lung toxicity
Speaker: J.S.A. Belderbos (The Netherlands)

Resectability after CCRT
Speaker: P. Van Schil (Belgium)

Discussion and Roundup

MONDAY 30 SEPTEMBER 2013

Teaching Lecture: Upfront Palliation Improves Survival in NSCLC
- 8:00 - 8:45
Speaker: C. Dooms (Belgium)

Scientific Symposium: Treatment Planning of Lung Cancer Using Innovative Therapy
- 9:00 - 11:00
Chair: M. Baumann (Germany)
Chair: S. Burgers (The Netherlands)

Introduction - Case presentation
Speaker: M. Baumann (Germany)

Latest developments in Imaging
Speaker: C. Fink (Germany)

Drug uptake – monitoring and prediction
Speaker: S. Burgers (The Netherlands)

Radiomics in lung cancer and outcomes
Speaker: P. Lambin (The Netherlands)

Concluding Remarks
Speaker: S. Burgers (The Netherlands)

Debate: This House Believes in 5 years the Majority of Non-Small Cell Lung Cancers Will be Treated With Targeted Therapies
- 17:00 - 18:00
Moderator: L. Paz Ares (Spain)
Speaker in favour: R. Dziadziuszko (Poland)
Speaker against: T. Le Chevalier (France)
Seconder in favour: M. Reck (Germany)
Seconder against: F. De Marinis (Italy)

Questions and answers with final vote

TUESDAY 1 OCTOBER 2013

Teaching Lecture: Practical Tips and Tricks With Recently Approved Molecular Targeted Agents in NSCLC
- 8:00 - 8:45
Speaker: S. Peters (Switzerland)

Special Session: The Pathology of Lung Cancer and its Clinical Implications
- 11:30 - 12:30
Chair: K. Kerr (United Kingdom)

Adenocarcinoma – from pathology to therapeutic implications
Speaker: W.D. Travis (USA)

Adenocarcinoma – from pathology to therapeutic implications
Speaker: D.R. Camidge (USA)

Squamous cell carcinoma – from pathology to therapeutic implications
Speaker: E. Brambilla (France)

Squamous cell carcinoma – from pathology to therapeutic implications
Speaker: J.C. Soria (France)

Discussion and Roundup

MELANOMA AND SKIN CANCER

SATURDAY 28 SEPTEMBER 2013

Scientific Symposium: New Classification of Melanoma and its Consequences for Treatment
- 16:00 - 18:00
Chair: J.A. Newton Bishop (United Kingdom)
Chair: M. Gore (United Kingdom)

Introduction
Speaker: J.A. Newton Bishop (United Kingdom)

Clinical consequences of sequencing (TBC)
Speaker: L. Garraway (USA)

Molecular Classification of Melanoma: Ready for Primetime?
Speaker: B.C. Bastian (USA)

New development in the Molecular Epidemiologic Field
Speaker: J.A. Newton Bishop (United Kingdom)

Heterogeneity of somatic alteration in melanoma
Speaker: R. Marais (United Kingdom)

Concluding Remarks
Speaker: M. Gore (United Kingdom)

SUNDAY 29 SEPTEMBER 2013

Teaching Lecture: Metastatic Melanoma: New Paradigms of Treatment and New Toxicities
- 8:00 - 8:45
Speaker: C. Robert (France)
Special Session: New Clinical Opportunities in Targeted Therapies
■ 17:00 - 18:00
Chair: M. Wouters (The Netherlands)
Combination modality treatment for brain metastases
Speaker: G. Long (Australia)
Combination treatment for irresectable melanoma masses
Speaker: O.E. Nieweg (The Netherlands)
Discussion and Roundup

MONDAY 30 SEPTEMBER 2013

Scientific Symposium: Do Resistance Mechanisms Require Combination Treatment in Immunomodulated and Targeted Therapies?
■ 14:45 - 16:45
Chair: C. Robert (France)
Introduction
Speaker: C. Robert (France)
New strategies for immunotherapies
Speaker: S.A. Quezada (United Kingdom)
Resistance mechanism to targeted agents
Speaker: K. Flaherty (USA)
Resistance mechanism to immunotherapy
Speaker: A. Ribas (USA)
Resistance to combination therapies
Speaker: F.S. Hodi (USA)
Concluding Remarks
Speaker: M. Gore (United Kingdom)

Special Session: New Treatment for Complex Basal Cell Carcinoma
■ 17:00 - 18:00
Chair: C. Garbe (Germany)
New treatment opportunity for non-resectable BCC
Speaker: N. Basset-Seguin (France)
Optimisation of hedgehog inhibitor use
Speaker: D. Schadendorf (Germany)
Discussion and Roundup

ONCOLOGY NURSING
SATURDAY 28 SEPTEMBER 2013

Opening Session: Oncology Nursing Opening and Award Session
❖ 10:30 - 11:00
Chair: B. Grube (Denmark)
Chair: E. van Muilekom (The Netherlands)

Scientific Symposium: The Impact of Cancer - Exploring Complexity and Special Needs in Specific Cancers
❖ 11:15 - 13:15
Chair: F. Charnay-Sonnek (France)
Chair: M. Wells (United Kingdom)

Introduction
Speaker: F. Charnay-Sonnek (France)
Life beyond cervical cancer
Speaker: C. Hughes (United Kingdom)
Life beyond head and neck cancer
Speaker: B. Noonan (Ireland)
Beyond lung cancer
Speaker: A. Serena (Switzerland)
Concluding Remarks
Speaker: M. Wells (United Kingdom)

Special Session: Young People Facing Cancer
❖ 14:15 - 15:15
Chair: D. Kelly (United Kingdom)
Update on evidence of delay in young people with cancer
Speaker: L. Fern (United Kingdom)
Quality of life in children and adolescents surviving cancer
Speaker: M.B. Eilertsen (Norway)
Providing age-appropriate care
Speaker: S. Smith (United Kingdom)
Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukaemia
Speaker: P.S. Hinds (USA)
Discussion and Roundup

Scientific Symposium: Cancer Pain Management Barriers: Can We Overcome Them?
❖ 16:00 - 18:00
Chair: Y. Wengström (Sweden)
Chair: S. Gunnarsdottir (Iceland)
Introduction
Speaker: Y. Wengström (Sweden)
Patient-related barriers
Speaker: S. Gunnarsdottir (Iceland)
Nurse-related barriers
Speaker: G. Borglin (Sweden)
Nursing interventions
Speaker: S. Piskorjanac (Croatia)
Changing the regulatory environment
Speaker: D. Mosoiu (Romania)
Concluding Remarks
Speaker: S. Gunnarsdottir (Iceland)

SUNDAY 29 SEPTEMBER 2013

Teaching Lecture: Collaborative International Oncology Nursing Research is Improving but Still a Long Way to go
❖ 8:00 - 8:45
Speaker: C. Tishelman (Sweden)

Scientific Symposium: Palliative Care in 2014
❖ 9:00 - 11:00
Chair: S.J. Swart (The Netherlands)
Chair: M. Bentzen (Denmark)
Introduction
Speaker: S.J. Swart (The Netherlands)
Physicians and nurses experiences’ with continuous palliative sedation
Speaker: S.J. Swart (The Netherlands)
Define future palliative care – should it form part of rehabilitation?
Speaker: P. Larkin (Ireland)
Xerostomia in palliative care
Speaker: L. Charalambous (Cyprus)
What competencies are required for basic and specialised palliative care?
Speaker: M. Bentzen (Denmark)
Concluding Remarks
Speaker: M. Bentzen (Denmark)
**Anniversary Session: EONS - 30th Anniversary: “Multidisciplinary Collaboration - Reflections on the past, Thinking Ahead for the Future”**

- **11:00 - 12:30**
  - Chair: E. van Muilekom (The Netherlands)
  - Multidisciplinary collaboration – EONS’ reflections on the past, thinking ahead for the future
    - Panel: B. Grube (Denmark)
  - Multidisciplinary collaboration – ECCO’s reflections on the past, thinking ahead for the future
    - Panel: C.J.H. van de Velde (The Netherlands)
  - Multidisciplinary collaboration – ESMO’s reflections on the past, thinking ahead for the future
    - Panel: M. Piccart (Belgium)
  - Multidisciplinary collaboration – ESSO’s reflections on the past, thinking ahead for the future
    - Panel: P. Naredi (Sweden)
  - Multidisciplinary collaboration – ESTRO’s reflections on the past, thinking ahead for the future
    - Panel: V. Valentini (Italy)
  - Multidisciplinary collaboration – SIOPE’s reflections on the past, thinking ahead for the future
    - Panel: To be announced

**Interactive Workshop: How to Win Friends and Influence (the right) People!**

- **13:15 - 14:15**
  - Coordinator: D. Benton (Switzerland)
  - How do we make our voice heard in the political arena? Are nurses political enough? How do we make sure that cancer nurses are being heard in politics, and that we together with patients makes sure that the health care system are doing the best for cancer patients!

**Special Session: Hope Across Cancer Care**

- **17:00 - 18:00**
  - Chair: E. van Muilekom (The Netherlands)
  - Portraying hope - a study among woman newly diagnosed with gynecological cancer
    - Speaker: K. Hammer (Denmark)
  - Nurses’ perspective of hope in cancer care
    - Speaker: E. Benzein (Sweden)
  - Hope at end of life care: when hope is all that is left
    - Speaker: H.W.M van Laarhoven (The Netherlands)

**Monday 30 September 2013**

- **Teaching Lecture: Benefits and Challenges Perceived by Patients With Cancer When Offered a Nurse Navigator**
  - **8:00 - 8:45**
    - Speaker: M.K. Thygesen (Denmark)

- **Scientific Symposium: Technology Issues: Healthcare 2.0**
  - **9:00 - 11:00**
    - Chair: L. Sharp (Sweden)
    - Chair: To be announced
    - Introduction
      - Speaker: L. Sharp (Sweden)
    - E-health is empowered health
      - Speaker: L. Engelen (The Netherlands)
    - Patients’ experience in dealing with technology
      - Speaker: J. Pelouchoua (Czech Republic)
    - Nurses’ experience in dealing with technology
      - Speaker: R. Fraser (Canada)

  - **Concluding remarks**
    - Speaker: To be announced

**Special Session: Survivorship and Follow up**

- **13:15 - 14:15**
  - Chair: J. Midtgaard (Denmark)
  - Exercise for cancer survivors
    - Speaker: J. Midtgaard (Denmark)
  - Using technology in supportive cancer care
    - Speaker: S. Kaasa (Norway)

**Scientific Symposium: The Elderly Cancer Patient**

- **14:45 - 16:45**
  - Chair: B.A. Esbensen (Denmark)
  - Chair: L. Noens (Belgium)
  - Introduction
    - Speaker: B.A. Esbensen (Denmark)
  - Adherence in elderly patients
    - Speaker: L. Noens (Belgium)
  - Polypharmacy in the elderly patient
    - Speaker: To be announced
  - The geriatric navigator/assessment
    - Speaker: B.A. Esbensen (Denmark)

- **Concluding Remarks**
  - Speaker: L. Noens (Belgium)
Debate: This House Believes That Personalised Medicine Should be Called Personalised Treatment and Care

Moderator: To be announced
Speaker in favour: B. Grube (Denmark)
Speaker against: A. Paradiso (Italy)
Seconder in favour: J. Pelouchova (Czech Republic)
Seconder against: D. Jacqmin (France)

Questions and answers with final vote

Tuesday 1 October 2013

Teaching Lecture: Cancer Nursing Training Programme for Community Nurses

Speaker: J.P. Richmond (Ireland)

Interactive Workshop: Nurses Facing Non-communicable Diseases – A Threat to Future Health?

Coordinator: B. Grube (Denmark)

People with non-communicable diseases (NCDs) often have many diseases at the same time. Nurses play a significant role in meeting this healthcare challenge. Advanced nurse practitioners are already taking care of the prevention, treatment and care of people with NCDs and more community nurses will be needed, as comorbidity and NCDs pose a huge threat for our future health. Changes in the organisation of healthcare systems may also be required. Politicians’ awareness should be raised at international level.

Scientific Symposium: How to Put Evidence into Daily Nursing Practice

Chair: A. Margulies (Switzerland)
Chair: L. Sharp (Sweden)

Introduction
Speaker: A. Margulies (Switzerland)

Lymphedema – prevention and treatment in daily practice
Speaker: M. Sneddon (United Kingdom)

Peripheral neuropathy, dealing with a difficult side effect
Speaker: A. Margulies (Switzerland)

Dyspnea - an oncological challenge
Speaker: A. Dales (Belgium)

Pain management is essential
Speaker: B. Quinn (United Kingdom)

Radiodermatitis-releasing skin problems
Speaker: L. Sharp (Sweden)

Concluding Remarks
Speaker: L. Sharp (Sweden)

Special Session: Advanced Practitioner Role in Cancer Care: Where Next?

Chair: P. Trevatt (United Kingdom)

Developing appropriate education programmes in advanced nursing practice: the Irish experience
Speaker: E. Furlong (Ireland)

Establishing the advanced nursing practitioner role for adolescents with cancer
Speaker: S. Smith (United Kingdom)

Advantages of nurse-led follow up
Speaker: E. van Muilekom (The Netherlands)

Discussion and Roundup

ONCOPOLICY

Sessions: To be announced
Monday 30 September 2013

Scientific Symposium: Chip Technologies

14:45 - 16:45

Chair: To be announced

Introduction

Speaker: To be announced

The impact of chip technology on cancer medicine

Speaker: M. Fey (Switzerland)

Direct profiling of cancer biomarkers using novel chip technology

Speaker: S.O. Kelley (Canada)

Lab-on-chip tracing circulating tumour cells

Speaker: L. Lagae (Belgium)

Biosensor chip in detection of cancer

Speaker: S. Nagrath (USA)

Discussion and Roundup

Tuesday 1 October 2013

Scientific Symposium: Enhancing Conventional Oncological Treatments With New Technologies

9:00 - 11:00

Chair: S. Krishnan (USA)

Chair: J. Pignol (Canada)

Introduction

Speaker: S. Krishnan (USA)

Light-activated multimodal nanoparticles

Speaker: M.P. Melancon (USA)

Radiosensitisation by gold nanoparticles at megavoltage radiation energies

Speaker: F. Currell (Ireland)

Effectiveness of electrochemotherapy in brain tumours

Speaker: J. Gehl (Denmark)

Multicomponent nanoparticles for enhanced delivery of chemotherapy

Speaker: To be announced

Concluding Remarks

Speaker: J. Pignol (Canada)

Friday 27 September 2013

Scientific Symposium: Cancer in Teenage and Young Adult

11:15 - 13:15

Chair: S. Bielack (Germany)

Chair: I.J. Lewis (United Kingdom)

Introduction

Speaker: S. Bielack (Germany)

Specialist care for teenager and young adults with cancer

Speaker: I.J. Lewis (United Kingdom)

Specialist care for teenager and young adults with cancer

Speaker: A. Ferrari (Italy)

Developing multi-professional education for TYA with cancer

Speaker: D. Stark (United Kingdom)

Improving access to clinical trials for teenagers and young adults

Speaker: L. Brugieres (France)

Role of patients and advocacy groups

Speaker: S. Morgan (United Kingdom)

Concluding Remarks

Speaker: I.J. Lewis (United Kingdom)

Sunday 29 September 2013

Teaching Lecture: By-passing the Blood Brain Barrier in Paediatric Oncology

8:00 - 8:45

Speaker: M. Vloeberghs (United Kingdom)

Monday 30 September 2013

Scientific Symposium: Empowering Survivors of Childhood and Adolescent Cancer

9:00 - 11:00

Chair: L.J. Hjorth (Sweden)

Chair: K. Pritchard-Jones (United Kingdom)

Introduction

Speaker: L.J. Hjorth (Sweden)

Special Session: Repainting and Tracking in Ion Beam Therapy

11:30 - 12:30

Chair: M. Schwartz (Italy)

Motion mitigation using scanned beams with moving targets

Speaker: A. Knopf (Switzerland)

Carbon ion beam tracking system

Speaker: C. Bert (Germany)

Discussion and Roundup

Special Session: New Insights into Biology of Brain Tumours

13:45 - 14:15

Chair: D. Walker (United Kingdom)

Histones and pediatric high grade gliomas

Speaker: C. Jones (United Kingdom)

Biology of low grade gliomas

Speaker: D. Jones (Germany)

Biomarkers in Ependymoma

Speaker: J. Grill (France)

Discussion and Roundup

Scientific Symposium: Treatment of Rhabdomyosarcoma in Children and Adolescents Across the Atlantic: Time for Increasing Joint Initiatives?

14:45 - 16:45

Chair: H. Hasle (Denmark)

Chair: D.S. Hawkins (USA)

Introduction

Speaker: H. Hasle (Denmark)

Reducing radiation therapy for children with rhabdomyosarcoma: results of the European strategy

Speaker: O. Oberlin (France)

Progress in the treatment of rhabdomyosarcoma: results of the North American strategy

Speaker: D.S. Hawkins (USA)

Treatment of relapsed rhabdomyosarcoma

Speaker: E. Koscielniak (Germany)

Biology-driven strategy for new drug development in Rhabdomyosarcoma

Speaker: J. Chisholm (United Kingdom)

Concluding Remarks

Speaker: D.S. Hawkins (USA)

Scientific Symposium: Enhancing Conventional Oncological Treatments With New Technologies

9:00 - 11:00

Chair: S. Krishnan (USA)

Chair: J. Pignol (Canada)

Introduction

Speaker: S. Krishnan (USA)

Light-activated multimodal nanoparticles

Speaker: M.P. Melancon (USA)

Radiosensitisation by gold nanoparticles at megavoltage radiation energies

Speaker: F. Currell (Ireland)

Effectiveness of electrochemotherapy in brain tumours

Speaker: J. Gehl (Denmark)

Multicomponent nanoparticles for enhanced delivery of chemotherapy

Speaker: To be announced

Concluding Remarks

Speaker: J. Pignol (Canada)

Scientific Symposium: Cancer in Teenage and Young Adult

11:15 - 13:15

Chair: S. Bielack (Germany)

Chair: I.J. Lewis (United Kingdom)

Introduction

Speaker: S. Bielack (Germany)

Specialist care for teenager and young adults with cancer

Speaker: I.J. Lewis (United Kingdom)

Specialist care for teenager and young adults with cancer

Speaker: A. Ferrari (Italy)

Developing multi-professional education for TYA with cancer

Speaker: D. Stark (United Kingdom)

Improving access to clinical trials for teenagers and young adults

Speaker: L. Brugieres (France)

Role of patients and advocacy groups

Speaker: S. Morgan (United Kingdom)

Concluding Remarks

Speaker: I.J. Lewis (United Kingdom)

Teaching Lecture: By-passing the Blood Brain Barrier in Paediatric Oncology

8:00 - 8:45

Speaker: M. Vloeberghs (United Kingdom)

Special Session: New Insights into Biology of Brain Tumours

13:45 - 14:15

Chair: D. Walker (United Kingdom)

Histones and pediatric high grade gliomas

Speaker: C. Jones (United Kingdom)

Biology of low grade gliomas

Speaker: D. Jones (Germany)

Biomarkers in Ependymoma

Speaker: J. Grill (France)

Discussion and Roundup

Scientific Symposium: Treatment of Rhabdomyosarcoma in Children and Adolescents Across the Atlantic: Time for Increasing Joint Initiatives?

14:45 - 16:45

Chair: H. Hasle (Denmark)

Chair: D.S. Hawkins (USA)

Introduction

Speaker: H. Hasle (Denmark)

Reducing radiation therapy for children with rhabdomyosarcoma: results of the European strategy

Speaker: O. Oberlin (France)

Progress in the treatment of rhabdomyosarcoma: results of the North American strategy

Speaker: D.S. Hawkins (USA)

Treatment of relapsed rhabdomyosarcoma

Speaker: E. Koscielniak (Germany)

Biology-driven strategy for new drug development in Rhabdomyosarcoma

Speaker: J. Chisholm (United Kingdom)

Concluding Remarks

Speaker: D.S. Hawkins (USA)

Scientific Symposium: Enhancing Conventional Oncological Treatments With New Technologies

9:00 - 11:00

Chair: S. Krishnan (USA)

Chair: J. Pignol (Canada)

Introduction

Speaker: S. Krishnan (USA)

Light-activated multimodal nanoparticles

Speaker: M.P. Melancon (USA)

Radiosensitisation by gold nanoparticles at megavoltage radiation energies

Speaker: F. Currell (Ireland)

Effectiveness of electrochemotherapy in brain tumours

Speaker: J. Gehl (Denmark)

Multicomponent nanoparticles for enhanced delivery of chemotherapy

Speaker: To be announced

Concluding Remarks

Speaker: J. Pignol (Canada)
What is the issue? The survivor's view
Speaker: A. Brownsdon (United Kingdom)

Genetic predisposition to late complications after cancer treatment – what do we know?
Speaker: T. Langer (Germany)

Non-visible subtle long-term complications to treatment – what are they, how do we find them and what do we do?
Speaker: H. van der Pal (The Netherlands)

Health passport for risk-adapted follow up
Speaker: R. Haupt (Italy)

Concluding Remarks
Speaker: K. Pritchard-Jones (United Kingdom)

Special Session: Shared Challenges of Small Group Trials
13:15 - 14:15
Chair: M.G. Valsecchi (Italy)

Principles of adaptive designs and application
Speaker: A. Faldum (Germany)

Multi-arm multi-stage studies for speeding the process of new drug evaluation
Speaker: M. Parmar (United Kingdom)

Bayesian designs in early phase trials
Speaker: P.F. Thall (USA)

Discussion and Roundup

Scientific Symposium: Targeted Drugs and Personalised Medicine in Paediatric Oncology
14:45 - 16:45
Chair: G. Vassal (France)
Chair: M. Schrappe (Germany)

Introduction
Speaker: G. Vassal (France)

B-Raf as a druggable target in paediatric malignancies
Speaker: D. Hargrave (United Kingdom)

Targeting the sonic hedgehog pathway in paediatric malignancies
Speaker: B. Geoerger (France)

Targeting the mTOR/AKT/PI3K pathway in paediatric malignancies
Speaker: A. Pearson (United Kingdom)

Changing role of immunotherapy in neuroblastoma
Speaker: H. Lode (Germany)

Concluding Remarks
Speaker: M. Schrappe (Germany)

PATIENT ADVOCACY/ETHICS

Saturday 28 September 2013
This Week on Talking About Cancer With Richard Sullivan: A Mock Talk Show
11:15 - 13:15
Chair: K. Oliver (United Kingdom)
Chair: J. Pelouchova (Czech Republic)
Speaker: I. Banks (United Kingdom)

Session details: To be announced

Personalized Medicine
14:15 - 15:15
Chair: R. Catane (Israel)
Chair: S. Diler (Turkey)

Session details: To be announced

Cancer: now what? Returning to Normal Life
16:00 - 18:00
Chair: J. Kelly (Ireland)

Session details: To be announced

Sunday 29 September 2013
Best Practices: Advocacy – Didn’t we do Well?
9:00 - 11:00
Chair: J. Geissler (Germany)
Chair: K. Redmond (Switzerland)

Session details: To be announced

Panel Discussion: Quality of Life / Palliative Care - Do Patients Perceive Quality of Life the same way as Their Doctors do?
11:15 - 12:00
Chair: T. Hudson (Belgium)
Chair: S. Erdem (Turkey)

Adherence to Cancer Treatment: is it Worth it?
13:15 - 14:15
Chair: J. Gore-Booth (France)

Session details: To be announced
Some Patients are More Equal Than Others – Satnav Cancer: Where do I Find the Best?

* 14:45 - 16:45

Chair: I. Banks (United Kingdom)
Chair: J. Geissler (Germany)

Session details: To be announced

---

Empowering Young People With Cancer – a Passport for Survivors

* 17:15 - 18:15

Chair: G. Bode (Germany)
Session details: To be announced

---

RADIOBIOLOGY/RADIATION PHYSICS/RADIOTHERAPY

SATURDAY 28 SEPTEMBER 2013

---

Teaching Lecture: Immunotherapy and Radiation

* 8:00 - 8:45

Speaker: S. Formenti (Italy)

---

Special Session: Immune System Radiation Interactions

* 14:15 - 15:15

Chair: J.J. Neefjes (The Netherlands)

Radiation-induced changes in immune activation
Speaker: M.H. Barcellos-Hoff (USA)

Immune modulation and radiotherapy: Ipilimumab and melanoma
Speaker: J. Wolchok (USA)

Discussion and Roundup

---

Scientific Symposium: Novel Targets in Radiation Oncology

* 16:00 - 18:00

Chair: M. Verheij (The Netherlands)
Chair: H.P. Rodemann (Germany)

Introduction
Speaker: M. Verheij (The Netherlands)

---

In vitro and in vivo discovery of novel targets using functional genomics
Speaker: B. Wouters (Canada)

Modifying checkpoint signaling for radiosensitization
Speaker: R. Syljusden (Norway)

Targeting oxygen metabolism to improve radiotherapy
Speaker: M. Kortzinsby (Canada)

Focal adhesion as important determinant of radiation survival
Speaker: N. Cordes (Germany)

Concluding Remarks
Speaker: H.P. Rodemann (Germany)

---

SUNDAY 29 SEPTEMBER 2013

---

Teaching Lecture: EGFR Targeting and its Role for Individualisation in Radiation Oncology

* 8:00 - 8:45

Speaker: M. Krause (Germany)

---

Special Session: How Should Complex Treatments in Radiation Therapy be Monitored to Guarantee Quality?

* 13:15 - 14:15

Chair: N. Jornet (Spain)

In vivo dosimetry
Speaker: L. McDermott (The Netherlands)

A comprehensive QA programme of treatment unit and treatment planning systems would make pre-treatment verifications redundant
Speaker: D. Verellen (Belgium)

Discussion and Roundup

---

MONDAY 30 SEPTEMBER 2013

---

Teaching Lecture: Cancer Invasion and Resistance

* 8:00 - 8:45

Speaker: P. Friedl (The Netherlands)

---

Special Session: MRI and Radiation Therapy in Prostate Cancer: Optimisation of Targeting and Delivery

* 13:15 - 14:15

Chair: K. Haustermans (Belgium)

MRI-guided brachytherapy
Speaker: P. Hoskin (United Kingdom)

---

MRI-guided external beam
Speaker: U.A. van der Heide (The Netherlands)

Discussion and Roundup

---

Scientific Symposium: Evidence-based Radiation Oncology: The Large Database Perspective

* 14:45 - 16:45

Chair: J. Overgaard (Denmark)
Chair: S.M. Bentzen (USA)

Introduction
Speaker: J. Overgaard (Denmark)

---

Biomedical knowledge integration: The ontology platform

Speaker: R.K. Chhem (Austria)

Promoting evidence through image features from radiographic images: The Radiomic Consortium
Speaker: H. Aerts (The Netherlands)

Promoting evidence through correlation of radiology information to genomic data: The Radiogenomic Consortium
Speaker: C. West (United Kingdom)

Promoting evidence by methods from large clinical databases: The EURECCA Consortium
Speaker: V. Valentini (Italy)

Concluding Remarks
Speaker: S.M. Bentzen (USA)

---

Debate: This House Believes That New Technologies in RT do not Require Randomised Clinical Trials

* 17:00 - 18:00

Moderator: J. Bourhis (France)

Speaker in favour: A. Dekker (The Netherlands)
Speaker against: H. Bartelink (The Netherlands)
Seconder in favour: R. Sullivan (United Kingdom)
Seconder against: L. Collette (Belgium)

Questions and answers with final vote

---

TUESDAY 1 OCTOBER 2013

---

Teaching Lecture: Therapeutic Procedures in Liver Metastases: Conventional and Future Measures

* 8:00 - 8:45

SBRT for which patient?
Speaker: L.A. Dawson (Canada)
Scientific Symposium: Innovative Molecular Imaging Strategies for Radiotherapy Individualisation

9:00 - 11:00

Chair: D. De Ruysscher (The Netherlands)
Chair: E. Moyal (France)

Introduction
Speaker: D. De Ruysscher (The Netherlands)

What reliable knowledge can molecular imaging offer nowadays to radiation oncologists?
Speaker: W.J.G. Oyen (The Netherlands)

Cetuximab Zirconium, a new generation of functional imaging
Speaker: F. Hoebers (The Netherlands)

Hypoxia-PET and its predictive value in HNSCC
Speaker: M. Baumann (Germany)

Amino acid PET
Speaker: A.L. Grosu (Germany)

Concluding Remarks
Speaker: E. Moyal (France)

SUNDAY 29 SEPTEMBER 2013

Special Session: Matching p-values to Clinical Needs: Statistical Significance vs Clinical Relevance
13:15 - 14:15
Chair: A.F. Sobrero (Italy)

Payers perspective
Speaker: H. Gray (United Kingdom)

Practitioners’ perspective
Speaker: A.F. Sobrero (Italy)

Patient perspective
Speaker: I. Banks (United Kingdom)

Discussion and Roundup

Scientific Symposium: Outcome Measures in Clinical Trial Design?
14:45 - 16:45
Chair: J. Verweij (The Netherlands)
Chair: J. Doroshow (USA)

Introduction
Speaker: J. Doroshow (USA)

What defines a validated biological biomarker? A pharmacodynamics measurement or a patient-related or related outcome?
Speaker: J. Verweij (The Netherlands)

What is the best measure for patient benefit?
Speaker: E.A. Eisenhauer (Canada)

Technical pitfalls of measuring biological biomarkers
Speaker: D.R. Parkinson (USA)

Cross over in oncology trials: considerations for endpoints and trial design - arguments pro and contra
Speaker: J. Doroshow (USA)

Concluding Remarks
Speaker: J. Verweij (The Netherlands)

Debate: This House Believes That Body Surface Area Based Dosing is a Misconception
17:00 - 18:00
Moderator: A. Sparreboom (USA)

Speaker in favour: M.J. Ratain (USA)
Speaker against: I. Judson (United Kingdom)
Seconder in favour: R. Mathijssen (The Netherlands)
Seconder against: E. Chatelut (France)

Questions and answers with final vote

MONDAY 30 SEPTEMBER 2013

Teaching Lecture: Development of New Dose-limiting Criteria for Oral (and chronically dosed) Agents in Phase I Studies
8:00 - 8:45
Speaker: J.C. Soria (France)

Scientific Symposium: Cancer Pharmaceutics
14:45 - 16:45
Chair: A. Astier (France)
Chair: C. Dittrich (Austria)

Introduction
Speaker: A. Astier (France)

Development of biosimilars
Speaker: H. Schellekens (The Netherlands)

Anticancer drug shortages
Speaker: G.J. Wiedemann (Germany)

Stability of biological anticancer drugs in practical situations
Speaker: A. Astier (France)

Ensuring prescription and delivery accuracy for cytotoxics
Speaker: K. Meier (Germany)

Is there a dose-effect relationship for biological anticancer drugs?
Speaker: L. Gianni (Italy)

Concluding Remarks
Speaker: C. Dittrich (Austria)

REGULATORY/TRIAL METHODOLOGY/PHARMACY

Saturday 28 September 2013

Special Session: Dilemma of Crossover in Clinical Trial Design of Agents With "Obvious Activity"
14:15 - 15:15
Chair: J. Bogaerts (Belgium)
Debate: This House Believes That the EU Clinical Trials Directive has Harmed European Clinical Studies

Moderator: J.S. de Bono (United Kingdom)
Speaker in favour: F. Meunier (Belgium)
Speaker against: C. Tomino (Italy)
Seconder in favour: P. G. Casali (Italy)
Seconder against: A. Yver (USA)

Questions and answers with final vote

SARCOMA: SOFT TISSUE AND BONE

Monday 30 September 2013

Special Session: Medical Treatment of GIST
13:15 - 14:15
Chair: P. G. Casali (Italy)
How to order the many different medical treatments?
Speaker: P. Reichardt (Germany)
Adjuvant treatment: to whom, how much and for how long?
Speaker: H. Joensuu (Finland)
How can molecular biology guide future research?
Speaker: J. Martin-Broto (Spain)
Discussion and Roundup

Scientific Symposium: Innovative Treatment Modalities in Sarcomas
14:45 - 16:45
Chair: P. G. Casali (Italy)
Chair: B. O’Sullivan (Canada)
Introduction
Speaker: P. G. Casali (Italy)
Proton or carbon ion therapy for chondrosarcomas and chordomas?
Speaker: J. Debus (Germany)
MDM2 and CDK4 as a therapeutic target in sarcomas
Speaker: J. Y. Blay (France)
Targeted treatment of Ewing sarcomas: Current status
Speaker: B. Hassan (United Kingdom)
Denosumab in giant cell tumours: When and for how long?
Speaker: S. Ferrari (Italy)
Concluding Remarks
Speaker: B. O’Sullivan (Canada)

Debate: This House Believes That Metastasis of Sarcoma Should be Removed if Complete Response is Achievable
17:00 - 18:00
Moderator: F. Van Coevorden (The Netherlands)
Speaker in favour: P. Hohenberger (Germany)
Speaker against: A. Gronchi (Italy)
Seconder in favour: P. Rutkowski (Poland)
Seconder against: A. Le Cesne (France)
Questions and answers with final vote

Tuesday 30 September 2013

Teaching Lecture: Role of Expert Centres in the Management of Sarcomas
8:00 - 8:45
Speaker: I. Judson (United Kingdom)

Special Session: Retropertioneal Sarcomas
11:30 - 12:30
Chair: P. Hohenberger (Germany)
Surgical aspects
Speaker: S. Bonvalot (France)
The role of radiotherapy
Speaker: R. Haas (The Netherlands)
The role of chemotherapy
Speaker: M. Montemurro (Switzerland)
Discussion and Roundup

Surgical Oncology

Saturday 28 September 2013

Teaching Lecture: Oncoplastic Surgery – Standard of Care
8:00 - 8:45
Speaker: A. D. Baildam (United Kingdom)

Special Session: Minimally Invasive Cancer Surgery: What is the Benefit?
14:15 - 15:15
Chair: S. Gonzalez-Moreno (Spain)
Robotic surgery
Speaker: D. Jayne (United Kingdom)

Notes
Speaker: R. A. Cahill (Ireland)
Laparoscopic surgery
Speaker: M. A. Cuesta (The Netherlands)
Discussion and Roundup

Sunday 29 September 2013

Teaching Lecture: Surgical Management of NET Liver Metastases
8:00 - 8:45
Speaker: P. Hellman (Sweden)

Special Session: Centralisation of Complex Cancer Surgery: Do Outcomes Improve?
13:15 - 14:15
Chair: G. Poston (United Kingdom)
US perspective
Speaker: M. Brennan (USA)
Swedish perspective
Speaker: P. Naredi (Sweden)
Dutch perspective
Speaker: M. Wouters (The Netherlands)
Discussion and Roundup

Scientific Symposium: Minimal Metastatic Pancreatic Cancer: Is it a Surgical Disease?
14:45 - 16:45
Chair: V. Heinemann (Germany)
Chair: D. J. Gouma (The Netherlands)
Introduction
Speaker: V. Heinemann (Germany)
Key criteria in imaging
Speaker: N. Albiin (Sweden)
Neoadjuvant therapy in estimating disease aggressiveness?
Speaker: D. Cunningham (United Kingdom)
Value of synchronous resection?
Speaker: M. W. Büchler (Switzerland)
Is local control an issue?  
Speaker: K. Haustermans (Belgium)

Concluding Remarks  
Speaker: D.J. Gouma (The Netherlands)

———

Special Session: Is There a Role for Surgery in the Management of HCC?  
❖ 17:00 - 18:00

Chair: H. Malik (United Kingdom)

Value of liver function tests and volumetry  
Speaker: P. Pessaux (France)

Limited vs anatomical resection  
Speaker: J. Belghiti (France)

Liver transplantation  
Speaker: V. Mazzaferro (Italy)

Discussion and Roundup

TUESDAY 1 OCTOBER 2013

Teaching Lecture: Mechanisms of Underlying Symptoms in Cancer Patients  
❖ 8:00 - 8:45

Speaker: C.S. Cleeland (USA)

Scientific Symposium: Diagnosis and Treatment of Oncological Emergencies  
❖ 9:00 - 11:00

Chair: T. Saarto (Finland)
Chair: J. Kazmierska (Poland)

Introduction  
Speaker: T. Saarto (Finland)

Malignant bowel obstruction: the surgeons’ perspective  
Speaker: W.A. Bemelman (The Netherlands)

Conservative treatment of malignant bowel obstruction  
Speaker: D. Currow (Australia)

Management of hemoptysis  
Speaker: J. Lehto (Finland)

Spinal cord compression  
Speaker: D. Rades (Germany)

Concluding Remarks  
Speaker: J. Kazmierska (Poland)

———

TRANSLATIONAL RESEARCH

SUNDAY 29 SEPTEMBER 2013

Scientific Symposium: Exploiting Defective DNA Damage Response Pathways in Tumours  
❖ 14:45 - 16:45

Chair: T. Helleday (Sweden)
Chair: A. Chalmers (United Kingdom)

Introduction  
Speaker: T. Helleday (Sweden)

Combining radiation therapy with DNA damage response inhibitors  
Speaker: A. Chalmers (United Kingdom)

New DNA repair targets in cancer treatment  
Speaker: T. Helleday (Sweden)

Exploiting cell cycle checkpoint defects in human tumours  
Speaker: Ó. Fernández-Capetillo (Spain)

Combining radiation therapy with cell cycle checkpoint inhibitors: pre-clinical data and clinical trial concepts  
Speaker: G. McKenna (United Kingdom)

Concluding Remarks  
Speaker: A. Chalmers (United Kingdom)

Monday 30 September 2013

Teaching Lecture: Next Generation Sequencing  
❖ 8:00 - 8:45

Speaker: L. Pusztai (USA)

Scientific Symposium: Immunology from Bench to Bedside  
❖ 9:00 - 11:00

Chair: C. Sotiriou (Belgium)
Chair: M. Smyth (Australia)

Introduction  
Speaker: C. Sotiriou (Belgium)

Translational biomarkers in immunotherapy  
Speaker: C. Sotiriou (Belgium)

Engaging in adaptive tumour response in cancer  
Speaker: M. Smyth (Australia)

Rational approaches in immunotherapy  
Speaker: S.A. Quezada (United Kingdom)
Immunology from bench to bedside
Speaker: G. Curigliano (Italy)

Concluding Remarks
Speaker: M. Smyth (Australia)

—

Special Session: The Mouse Hospital in Drug Development
Chair: R. Giavazzi (Italy)

GEM Models to facilitate drug development
Speaker: C. Nardella (United Kingdom)

Patient-Derived Xenografts for Enhancing Drug Development and Personalizing Patient Therapy
Speaker: D. Gandara (USA)

Are animal models in early drug development of use?
Speaker: K.L. Blanchard (China)

Discussion and Roundup

—

Scientific Symposium: Interrogating Minimal Residual Disease: What is New?
Chair: M. Ignatiadis (Belgium)
Chair: N. Rosenfeld (United Kingdom)

Introduction
Speaker: N. Rosenfeld (United Kingdom)

Circulating tumour cells as a liquid biopsy in breast cancer: are we there yet?
Speaker: M. Ignatiadis (Belgium)

Circulating tumour DNA sequencing: from targeted mutations to whole genome resolution
Speaker: Y.M.D. Lo (China)

Noninvasive monitoring of cancer dynamics using circulating tumour DNA
Speaker: N. Rosenfeld (United Kingdom)

Concluding Remarks
Speaker: M. Ignatiadis (Belgium)

YOUNG ONCOLOGIST

SATURDAY 28 SEPTEMBER 2013

Young Oncologists Mentorship Session
▲ 13:15 - 14:15
Session details: to be announced

SUNDAY 29 SEPTEMBER 2013

Young Oncologists Mentorship Session
▲ 9:00 - 10:00
Session details: to be announced

Special Session: How to be a Happy Oncologist
▲ 13:15 - 14:15
Chair: E. De Azambuja (Belgium)

Quality of life of young oncologists
Speaker: P. Blanchard (France)

Why choose oncology? How to identify goals/aims/barriers towards professional fulfillment for young oncologists
Speaker: P. Dubsky (Austria)

Managing burnout in oncology – special focus on young oncologists
Speaker: L. Fallowfield (United Kingdom)

Discussion and Roundup

Roundtable: How to Improve Career Opportunities for Young Oncologists Across Europe
▲ 17:00 - 18:00
Moderator: F. Cardoso (Portugal)

Young Oncologists Speakers

Greece
Speaker: D. Zardavas (Belgium)

Italy
Speaker: I. Meattini (Italy)

Spain
Speaker: E. Castrillo (United Kingdom)

The Netherlands
Speaker: S. Sleijfer (The Netherlands)

Discussion with Panel of Experts
Panel: J. Bergh (Sweden)
Panel: R. Audisio (United Kingdom)
Panel: M. Mangoni (Italy)

MONDAY 30 SEPTEMBER 2013

Special Session: Improving Hands-on Education for Young Oncologists
▲ 13:15 - 14:15
Chair: P. Blanchard (France)

Training surgical oncologists in Europe
Speaker: P. Naredi (Sweden)

Training medical oncologists in Europe
Speaker: J.F. Smyth (United Kingdom)

Training radiation oncologists in Europe
Speaker: R. Pötter (Austria)

Discussion and Roundup

Scientific Symposium: Integrating Genetic Information Into Daily Clinical Practice
▲ 14:45 - 16:45
Chair: S. Loibl (Germany)
Chair: S. Banerjee (United Kingdom)

Introduction
Speaker: S. Loibl (Germany)

Germline mutations and cancer susceptibility
Speaker: N. Rahman (United Kingdom)

Expression profiling in breast cancer: ready for clinical use?
Speaker: C. Sotiriou (Belgium)

Genetic analysis in advanced cancer patients: What test for which patient? Matching patient, biomarker and drug
Speaker: J. Rodon (Spain)

Impact of genetic analyses on patients - what to tell our patients?
Speaker: M. Abramowicz (Belgium)

Concluding Remarks
Speaker: S. Banerjee (United Kingdom)

Young Oncologists Mentorship Session
▲ 17:00 - 18:00
Session details: to be announced
Young Oncologists @ ECC 2013

Track & Mentoring Sessions

Progress in oncology is fast-moving; more medicines, treatment techniques, combinations and options are available than ever before, and new opportunities crop up on a regular basis. Keeping up-to-date on all this important information is essential to ensure better cancer treatment for patients. Young oncologists can usually obtain up-to-the-minute information and updates on clinical trials and other hot topics at congresses. However, wider, career-oriented support and information to help shape and encourage their interests and future work and is often lacking, as is mentoring and guidance from experienced professionals in avoiding mistakes that they themselves have made during their own career learning curve. That is why we have ensured that all this and more can be found as part of the Young Oncologist Track & Mentoring Sessions @ ECC 2013.

A special session on how to be a happy oncologist and a panel discussion on career progression across Europe have been designed to help guide young clinicians and scientists in affirming their professional personality, facilitating them in making an impact on the oncology community.

The European Cancer Congress also provides a platform to meet experts and fellow young oncologists enabling lifetime partnerships to be developed, which will further young oncologists’ career and, ultimately, provide the patients with the best possible treatment and care.

In addition, the congress will host a mentorship programme aiming to provide young oncologists the opportunity to speak to world-renowned experts in all disciplines.

As space is limited for these sessions, early registration is advised. Please register online, as part of the overall registration process: eccamsterdam2013.ecco-org.eu/Registration

Kindly note that you can only register online for these “ticketed sessions”.

To further promote multidisciplinary treatment and care, early morning tumour board meetings will be held with a multidisciplinary panel of experts discussing a number of organ-specific cases.

Last but not least, educational symposia and teaching lectures are available throughout the programme. These sessions are very popular with all participants and provide state-of-the-art information on cancer treatment, research and care. An online Education Book will support these sessions.

Flims Alumni Club

The Flims Alumni Club (FAC) will be organising a session based on the Flims Workshop. This workshop, held every year since 1999 in the small town of Flims, nestled in the Swiss mountains, introduces junior clinical oncologists to the principles of good clinical trials design.

The robust educational programme offers the most stimulating, interactive and multidisciplinary educational activity on clinical trial methodology in oncology. This session will be held on Monday 30 September 2013.
Get your research read by experts
Publish with the EJC

www.ejcancer.info
Editor-in-Chief:
Alexander M.M. Eggermont, Villejuif, France

The EJC is an international multidisciplinary oncology journal which publishes original research, clinical trials, editorial comments, review articles and news on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention.

Facts and Figures for the EJC:
• Rapid peer-review and decision process: average editorial decision in 3 weeks
• All accepted manuscripts are published online as Articles-in-Press within 4 - 5 weeks
• Open Access publishing options available
• Worldwide dissemination through ScienceDirect: 1.1 million article downloads in 2012
• EJC Impact Factor: 5.536* (Journal Citation Reports®, published by Thomson Reuters 2012)

The EJC is the official journal of the EORTC, ECCO, the EACR and EUSOMA

Free!
Download the EJC iPad app from iTunes to access content on-the-go www.apple.com/itunes

Scan the QR code

EJC
EUROPEAN JOURNAL OF CANCER

Publish with EJC, submit your article online at:
http://ees.elsevier.com/ejc

Follow us on Facebook!
facebook.com/OncologyAdvance
## European Cancer Congress 2013
Programme Tracks, Chairs and Experts

<table>
<thead>
<tr>
<th>Track</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| **Basic Science** | Anne-Lise Børresen-Dale NO  
Rene Bernards NL  
Fred Sweep NL  
Suzanne A. Eccles UK  
Kevin Ryan UK  
Dien Mosche UK  
Marie-Catherine Vezin-Brotons FR  
Brad Wouters CA  
Jacques Pouyssegur FR  
Fátima Candoso PT  
Luca Gianni IT  
Giuseppe Curigliano IT  
Fabrice Andre FR  
Lorenzo Livi IT  
Alain Fourquet FR  
Philippe Bedard CA  
Ian Smith UK  
Carlos Caldas UK  
Isabel T. Rubio ES  |
| **Breast cancer-advanced disease** | Robert E. Coleman UK  
Michael Gnant AT  
Sherene Loi BE  
Mohammed Keshtgar UK  
Evandro De Azambuja BE  
Philip Poortmans NL  
Nick Turner UK  
Carlos Caldas UK  
Isabel T. Rubio ES  |
| **Breast cancer-early disease** | Riccardo A. Audisio UK  
Hans Wildiers BE  
Laura Biganzoli IT  
Gerrit-Jan Liefers NL  
Johanna Portielje NL  
Eric Deutsch FR  
Pierre Scalliet BE  |
| **Cancer in the older patient** | Riccardo A. Audisio UK  
Hans Wildiers BE  
Laura Biganzoli IT  
Gerrit-Jan Liefers NL  
Johanna Portielje NL  
Eric Deutsch FR  
Pierre Scalliet BE  |
| **Central nervous system** | Riccardo Soffetti IT  
Wolfgang Wick DE  
Colin Watts UK  
Alba A. Brandes IT  
Michael Weller CH  
Roger Stupp CH  
Claus Beika DE  
Jean Sesane ES  
Elizabeth Cohen-jonathan-Moyal FR  
Simone Niclou LU  
Nadia Harbeck DE  
Jorge Rei-Filho UK  
Stefan Michiels BE  
Marc Van de Vijver NL  
Giuseppe Viale IT  
Michail Ignatiadis BE  
Robertus Tollefson NL  |
| **Drug development** | Chris Twelves UK  
Patrick Schoffski BE  
Jose Baselga US  
Cristiana Sessa CH  
Elizabeth A. Eisenhauer CA  
Gerhard A. Attard UK  
Jean-Pascal Machiels BE  
Annette K. Larsen FR  
Jan H.M. Schellens NL  
Kevin Harrington UK  
Filippo Guglielmo De Braud IT  
Ahmad Awada BE  |
| **Education Track** | Dirk Schrijvers BE  
Jean-Yves Souilard FR  
Lynda Wyld UK  
Richard Potter AT  
Verena Jendrossek DE  
Alberto Costa IT  
Nuria Jomet ES  
Theresie Sarlie NO  
Fabrice Andre FR  
Jean-Yves Blay FR  
Andres Cervantes Ruizperez ES  
Nathan Cherny IL  
Christian Ditztch AT  
Martin Dreyling DE  
Reinhard Dummer CH  
Robert Eckert DE  
Bernard Escudier FR  
Enrique Felipe ES  
Michele Ghelmini CH  
Richard Herrmann CH  
Jorn Herstedt DK  
Lorenz Jost CH  
Claus H. Koehne DE  
Pierre Laurent-Puig FR  
Jonathan Ledermann UK  
Marco Merlano IT  
George Pentheroudakis GR  
Nicholas Pavlidis GR  
Mauro A. Pierotti IT  
Hans-Joerg Senn CH  
Alberto F. Sobore IT  
Gianpaolo Torlone IT  
Michael Weller CH  
Gilbert Zulian CH  
Zdenko Herceg FR  
Jack Cuzick UK  
Philippe Autier FR  
Valery Lemmens NL  
Cornelia Ulrich DE  
David Forman FR  |
| **Epidemiology, primary and secondary prevention** | Zdenko Herceg FR  
Jack Cuzick UK  
Philippe Autier FR  
Valery Lemmens NL  
Cornelia Ulrich DE  
David Forman FR  |

Names in red denote Track Chairs
<table>
<thead>
<tr>
<th>Track</th>
<th>Gastrointestinal malignancies-colorectal cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
<tr>
<td></td>
<td>Jose Tabernero ES</td>
</tr>
<tr>
<td></td>
<td>Harm Rutten NL</td>
</tr>
<tr>
<td></td>
<td>Sören Laurberg DK</td>
</tr>
<tr>
<td></td>
<td>Anna Martling SE</td>
</tr>
<tr>
<td></td>
<td>Eric Van Cutsem BE</td>
</tr>
<tr>
<td></td>
<td>Owen J Sansom UK</td>
</tr>
<tr>
<td></td>
<td>Alberto F. Sobero IT</td>
</tr>
<tr>
<td></td>
<td>David Sebag-Montefiore UK</td>
</tr>
<tr>
<td></td>
<td>Karin Haustermans BE</td>
</tr>
<tr>
<td></td>
<td>Philip Quirke UK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Gastrointestinal malignancies-noncolorectal cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Donal Hollywood IE</td>
</tr>
<tr>
<td></td>
<td>Michel Duzereux FR</td>
</tr>
<tr>
<td></td>
<td>Roberto Labanca IT</td>
</tr>
<tr>
<td></td>
<td>Arnaud Roth CH</td>
</tr>
<tr>
<td></td>
<td>Graeme Poston UK</td>
</tr>
<tr>
<td></td>
<td>Marcel Verheij NL</td>
</tr>
<tr>
<td></td>
<td>Eli Pikarsky IL</td>
</tr>
<tr>
<td></td>
<td>Francois Giannarile FR</td>
</tr>
<tr>
<td></td>
<td>Thomas Lehner DE</td>
</tr>
<tr>
<td></td>
<td>Vincent Khoo UK</td>
</tr>
<tr>
<td></td>
<td>Manuela Schmidinger AT</td>
</tr>
<tr>
<td></td>
<td>Tom Powles UK</td>
</tr>
<tr>
<td></td>
<td>Arnulf Stenzl DE</td>
</tr>
<tr>
<td></td>
<td>Gerdke Daugaard DK</td>
</tr>
<tr>
<td></td>
<td>Peter Hoskin UK</td>
</tr>
<tr>
<td></td>
<td>James Larkin UK</td>
</tr>
<tr>
<td></td>
<td>John Fitzpatrick IR</td>
</tr>
<tr>
<td></td>
<td>George N. Thalman CH</td>
</tr>
<tr>
<td></td>
<td>Axel Heidenreich DE</td>
</tr>
<tr>
<td></td>
<td>Karim Fizazi FR</td>
</tr>
<tr>
<td></td>
<td>Johann Sebastian de Bono UK</td>
</tr>
<tr>
<td></td>
<td>Freddie Charles Hamdy UK</td>
</tr>
<tr>
<td></td>
<td>Avishy Sella IL</td>
</tr>
<tr>
<td></td>
<td>Alberto Briganti IT</td>
</tr>
<tr>
<td></td>
<td>Chris Parker UK</td>
</tr>
<tr>
<td></td>
<td>Theo de Reijke NL</td>
</tr>
<tr>
<td></td>
<td>Alberto Bossi FR</td>
</tr>
<tr>
<td></td>
<td>Gordon Rustin UK</td>
</tr>
<tr>
<td></td>
<td>Christine Haie-Méder FR</td>
</tr>
<tr>
<td></td>
<td>Antonio Casado ES</td>
</tr>
<tr>
<td></td>
<td>Caien Creutzberg NL</td>
</tr>
<tr>
<td></td>
<td>Charles Gillham IE</td>
</tr>
<tr>
<td></td>
<td>David Cibula CZ</td>
</tr>
<tr>
<td></td>
<td>René Verheijen NL</td>
</tr>
<tr>
<td></td>
<td>Nicoletta Colombo IT</td>
</tr>
<tr>
<td></td>
<td>Ate van der Zee NL</td>
</tr>
<tr>
<td></td>
<td>Roman Rouzier FR</td>
</tr>
<tr>
<td></td>
<td>Martin Dreyling DE</td>
</tr>
<tr>
<td></td>
<td>Michele Ghelmini IT</td>
</tr>
<tr>
<td></td>
<td>Carlos Montalbán ES</td>
</tr>
<tr>
<td></td>
<td>Sebastian Giebel PL</td>
</tr>
<tr>
<td></td>
<td>Jordi Esteve ES</td>
</tr>
<tr>
<td></td>
<td>Vittorio Montefusco IT</td>
</tr>
<tr>
<td></td>
<td>Manuel A. Pins ES</td>
</tr>
<tr>
<td></td>
<td>Jean-Louis Harousseau FR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Genitourinary malignancies-other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vincent Khoo UK</td>
</tr>
<tr>
<td></td>
<td>Manuela Schmidinger AT</td>
</tr>
<tr>
<td></td>
<td>Tom Powles UK</td>
</tr>
<tr>
<td></td>
<td>Arnulf Stenzl DE</td>
</tr>
<tr>
<td></td>
<td>Gerdke Daugaard DK</td>
</tr>
<tr>
<td></td>
<td>Peter Hoskin UK</td>
</tr>
<tr>
<td></td>
<td>James Larkin UK</td>
</tr>
<tr>
<td></td>
<td>John Fitzpatrick IR</td>
</tr>
<tr>
<td></td>
<td>George N. Thalman CH</td>
</tr>
<tr>
<td></td>
<td>Axel Heidenreich DE</td>
</tr>
<tr>
<td></td>
<td>Karim Fizazi FR</td>
</tr>
<tr>
<td></td>
<td>Johann Sebastian de Bono UK</td>
</tr>
<tr>
<td></td>
<td>Freddie Charles Hamdy UK</td>
</tr>
<tr>
<td></td>
<td>Avishy Sella IL</td>
</tr>
<tr>
<td></td>
<td>Alberto Briganti IT</td>
</tr>
<tr>
<td></td>
<td>Chris Parker UK</td>
</tr>
<tr>
<td></td>
<td>Theo de Reijke NL</td>
</tr>
<tr>
<td></td>
<td>Alberto Bossi FR</td>
</tr>
<tr>
<td></td>
<td>Gordon Rustin UK</td>
</tr>
<tr>
<td></td>
<td>Christine Haie-Méder FR</td>
</tr>
<tr>
<td></td>
<td>Antonio Casado ES</td>
</tr>
<tr>
<td></td>
<td>Caien Creutzberg NL</td>
</tr>
<tr>
<td></td>
<td>Charles Gillham IE</td>
</tr>
<tr>
<td></td>
<td>David Cibula CZ</td>
</tr>
<tr>
<td></td>
<td>René Verheijen NL</td>
</tr>
<tr>
<td></td>
<td>Nicoletta Colombo IT</td>
</tr>
<tr>
<td></td>
<td>Ate van der Zee NL</td>
</tr>
<tr>
<td></td>
<td>Roman Rouzier FR</td>
</tr>
<tr>
<td></td>
<td>Martin Dreyling DE</td>
</tr>
<tr>
<td></td>
<td>Michele Ghelmini IT</td>
</tr>
<tr>
<td></td>
<td>Carlos Montalbán ES</td>
</tr>
<tr>
<td></td>
<td>Sebastian Giebel PL</td>
</tr>
<tr>
<td></td>
<td>Jordi Esteve ES</td>
</tr>
<tr>
<td></td>
<td>Vittorio Montefusco IT</td>
</tr>
<tr>
<td></td>
<td>Manuel A. Pins ES</td>
</tr>
<tr>
<td></td>
<td>Jean-Louis Harousseau FR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Genitourinary malignancies-prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Axel Heidenreich DE</td>
</tr>
<tr>
<td></td>
<td>Karim Fizazi FR</td>
</tr>
<tr>
<td></td>
<td>Johann Sebastian de Bono UK</td>
</tr>
<tr>
<td></td>
<td>Freddie Charles Hamdy UK</td>
</tr>
<tr>
<td></td>
<td>Avishy Sella IL</td>
</tr>
<tr>
<td></td>
<td>Alberto Briganti IT</td>
</tr>
<tr>
<td></td>
<td>Chris Parker UK</td>
</tr>
<tr>
<td></td>
<td>Theo de Reijke NL</td>
</tr>
<tr>
<td></td>
<td>Alberto Bossi FR</td>
</tr>
<tr>
<td></td>
<td>Gordon Rustin UK</td>
</tr>
<tr>
<td></td>
<td>Christine Haie-Méder FR</td>
</tr>
<tr>
<td></td>
<td>Antonio Casado ES</td>
</tr>
<tr>
<td></td>
<td>Caien Creutzberg NL</td>
</tr>
<tr>
<td></td>
<td>Charles Gillham IE</td>
</tr>
<tr>
<td></td>
<td>David Cibula CZ</td>
</tr>
<tr>
<td></td>
<td>René Verheijen NL</td>
</tr>
<tr>
<td></td>
<td>Nicoletta Colombo IT</td>
</tr>
<tr>
<td></td>
<td>Ate van der Zee NL</td>
</tr>
<tr>
<td></td>
<td>Roman Rouzier FR</td>
</tr>
<tr>
<td></td>
<td>Martin Dreyling DE</td>
</tr>
<tr>
<td></td>
<td>Michele Ghelmini IT</td>
</tr>
<tr>
<td></td>
<td>Carlos Montalbán ES</td>
</tr>
<tr>
<td></td>
<td>Sebastian Giebel PL</td>
</tr>
<tr>
<td></td>
<td>Jordi Esteve ES</td>
</tr>
<tr>
<td></td>
<td>Vittorio Montefusco IT</td>
</tr>
<tr>
<td></td>
<td>Manuel A. Pins ES</td>
</tr>
<tr>
<td></td>
<td>Jean-Louis Harousseau FR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Lung cancer - localised/local regional</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Elisabeth G.E. de Vries NL</td>
</tr>
<tr>
<td></td>
<td>Mirjam J. Oyen NL</td>
</tr>
<tr>
<td></td>
<td>Francois Giammarile FR</td>
</tr>
<tr>
<td></td>
<td>Felix Moatti NYH BE</td>
</tr>
<tr>
<td></td>
<td>Vincent Greig NL</td>
</tr>
<tr>
<td></td>
<td>Peter Friedl NL</td>
</tr>
<tr>
<td></td>
<td>Sigrid Stroobants BE</td>
</tr>
<tr>
<td></td>
<td>Patrick Flam MS</td>
</tr>
<tr>
<td></td>
<td>Werner Langsteger AT</td>
</tr>
<tr>
<td></td>
<td>Dirk de Ruyschter NL</td>
</tr>
<tr>
<td></td>
<td>Imene Zerier UK</td>
</tr>
<tr>
<td></td>
<td>Michael Baumann DE</td>
</tr>
<tr>
<td></td>
<td>Paul Baas NL</td>
</tr>
<tr>
<td></td>
<td>Charles Swanton UL</td>
</tr>
<tr>
<td></td>
<td>Peter Harper UK</td>
</tr>
<tr>
<td></td>
<td>Daniel Zips NL</td>
</tr>
<tr>
<td></td>
<td>Joachim Pfannenschmidt DE</td>
</tr>
<tr>
<td></td>
<td>Philippe Lambin NL</td>
</tr>
<tr>
<td></td>
<td>Jean Charles Sona FR</td>
</tr>
<tr>
<td></td>
<td>Paul Baas NL</td>
</tr>
<tr>
<td></td>
<td>Rolf Lewensohn SE</td>
</tr>
<tr>
<td></td>
<td>Benjamin Besse FR</td>
</tr>
<tr>
<td></td>
<td>Giorgio Scagliotti IT</td>
</tr>
<tr>
<td></td>
<td>Filippo De Marinis IT</td>
</tr>
<tr>
<td></td>
<td>Rolf Stahel CH</td>
</tr>
<tr>
<td></td>
<td>Martin Gore UK</td>
</tr>
<tr>
<td></td>
<td>Caroline Robert FR</td>
</tr>
<tr>
<td></td>
<td>Richard Morais UL</td>
</tr>
<tr>
<td></td>
<td>Lia Verhoef NL</td>
</tr>
<tr>
<td></td>
<td>Michel Wouters NL</td>
</tr>
<tr>
<td></td>
<td>Alexander M.M. Eggermont FR</td>
</tr>
<tr>
<td></td>
<td>Tim Eisen UK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Lung cancer - metastatic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Caroline Robert FR</td>
</tr>
<tr>
<td></td>
<td>Richard Morais UL</td>
</tr>
<tr>
<td></td>
<td>Mia Verhoef NL</td>
</tr>
<tr>
<td></td>
<td>Michel Wouters NL</td>
</tr>
<tr>
<td></td>
<td>Alexander M.M. Eggermont FR</td>
</tr>
<tr>
<td></td>
<td>Tim Eisen UK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Melanoma and skin cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Martin Dreyling DE</td>
</tr>
<tr>
<td></td>
<td>Michele Ghelmini IT</td>
</tr>
<tr>
<td></td>
<td>Carlos Montalbán ES</td>
</tr>
<tr>
<td></td>
<td>Sebastian Giebel PL</td>
</tr>
<tr>
<td></td>
<td>Jordi Esteve ES</td>
</tr>
<tr>
<td></td>
<td>Vittorio Montefusco IT</td>
</tr>
<tr>
<td></td>
<td>Manuel A. Pins ES</td>
</tr>
<tr>
<td></td>
<td>Jean-Louis Harousseau FR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Track</th>
<th>Oncology Nursing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Birgitte Grube DK</td>
</tr>
<tr>
<td></td>
<td>Erik van MuijlekomNL</td>
</tr>
<tr>
<td></td>
<td>Patricia Fox IE</td>
</tr>
<tr>
<td></td>
<td>Paul Trevatt UL</td>
</tr>
<tr>
<td></td>
<td>Elisabeth Patiraki CR</td>
</tr>
<tr>
<td></td>
<td>Sultan Kav TR</td>
</tr>
<tr>
<td></td>
<td>Françoise Charnay-Sonnek FR</td>
</tr>
<tr>
<td></td>
<td>Sophie Bunske NL</td>
</tr>
</tbody>
</table>
## Oncopolicy

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Julio Celis</td>
<td>DK</td>
</tr>
<tr>
<td></td>
<td>Razvan Popenescu</td>
<td>CH</td>
</tr>
<tr>
<td></td>
<td>Eduardo Cazap</td>
<td>AR</td>
</tr>
<tr>
<td></td>
<td>Thomas Tursz</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>John F Smyth</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Michael Baumann</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Paolo Casali</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Alexander M.M. Eggermont</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Cornelis van de Velde</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Marco Pierotti</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Kathy Redmond</td>
<td>IE</td>
</tr>
<tr>
<td></td>
<td>Ulrik Ringborg</td>
<td>SE</td>
</tr>
<tr>
<td></td>
<td>Olmar Wiestler</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Philippe Busquin</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>José Mariano-Gago</td>
<td>PT</td>
</tr>
<tr>
<td></td>
<td>Frank Cannon</td>
<td>IE</td>
</tr>
<tr>
<td></td>
<td>Peter Lange</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Federico Mayor-Zaragoza</td>
<td>ES</td>
</tr>
</tbody>
</table>

## Oncotechnology and Bioengineering

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dirk Verellen</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Dag Rune Olsen</td>
<td>NO</td>
</tr>
<tr>
<td></td>
<td>Rosalind Perrin</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>David Jaffray</td>
<td>CA</td>
</tr>
<tr>
<td></td>
<td>Katja Panodi</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Julian Malicki</td>
<td>PL</td>
</tr>
<tr>
<td></td>
<td>Ludwig P Muren</td>
<td>DK</td>
</tr>
<tr>
<td></td>
<td>Nuria Jornet</td>
<td>ES</td>
</tr>
</tbody>
</table>

## Paediatric oncology

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gilles Vassal</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Martin Schrappe</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Ruth Ladenstein</td>
<td>AT</td>
</tr>
<tr>
<td></td>
<td>Maria Grazia Valsecchi</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>David Walker</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Stefan Bielack</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Henrik Hasle</td>
<td>DK</td>
</tr>
<tr>
<td></td>
<td>Kathy Pritchard-jones</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Jan Banks</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Rafael Catane</td>
<td>IL</td>
</tr>
<tr>
<td></td>
<td>Hendrik Van Poppel</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Gerlind Bode</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Sarper Diler</td>
<td>TK</td>
</tr>
<tr>
<td></td>
<td>Sema Erdem</td>
<td>TK</td>
</tr>
<tr>
<td></td>
<td>Jan Geissler</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Jola Gore-Booth</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Tom Hudson</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Joan Kelly</td>
<td>IE</td>
</tr>
<tr>
<td></td>
<td>Kathy Oliver</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Jana Peloucova</td>
<td>AT</td>
</tr>
</tbody>
</table>

## Patient advocacy/ethics

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mechthild Krause</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Vincenzo Valenti</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Michael Baumann</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Nils Cordes</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Dirk Verellen</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Marianne Kontzinski</td>
<td>CA</td>
</tr>
<tr>
<td></td>
<td>Varena Jendrosek</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Philippe Lambin</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Brad Wouters</td>
<td>CA</td>
</tr>
<tr>
<td></td>
<td>Nuria Jornet</td>
<td>ES</td>
</tr>
<tr>
<td></td>
<td>Thomas Helleday</td>
<td>SE</td>
</tr>
</tbody>
</table>

## Regulatory/trial methodology/pharmacy

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jaap Verweij</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Jan Bogaerts</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Denis Lacombe</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Francesco Pignatti</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Christian Dittrich</td>
<td>AT</td>
</tr>
<tr>
<td></td>
<td>Martin van den Bent</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Max Parmar</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Alain Astier</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Sandra Horning</td>
<td>US</td>
</tr>
<tr>
<td></td>
<td>Mikael Daouphars</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>David Thompson</td>
<td>US</td>
</tr>
</tbody>
</table>

## Sarcoma: soft tissue and bone

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Brian O’Sullivan</td>
<td>CA</td>
</tr>
<tr>
<td></td>
<td>Jean-Yves Blay</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Axel Le Ceust</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Cecile Le Pechoux</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Patrick Schoffski</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Øyvind Bruland</td>
<td>NO</td>
</tr>
<tr>
<td></td>
<td>Paolo G Casali</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Peter Hohenberger</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Stefan Slijefer</td>
<td>NL</td>
</tr>
</tbody>
</table>

## Surgical Oncology

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Marijut Leidenius</td>
<td>FI</td>
</tr>
<tr>
<td></td>
<td>Graeme Poston</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Emiel J. Rutgers</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Peter Naredi</td>
<td>SE</td>
</tr>
<tr>
<td></td>
<td>Thomas Gruenberger</td>
<td>AT</td>
</tr>
<tr>
<td></td>
<td>Santiago Gonzalez-Moreno</td>
<td>ES</td>
</tr>
<tr>
<td></td>
<td>Thomas Lehnert</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Riccardo A. Audiso</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Beate Rau</td>
<td>DE</td>
</tr>
</tbody>
</table>

## Symptom science

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Joanna Kazmierska</td>
<td>PL</td>
</tr>
<tr>
<td></td>
<td>Tina Saarto</td>
<td>FI</td>
</tr>
<tr>
<td></td>
<td>Maído Dicato</td>
<td>LU</td>
</tr>
<tr>
<td></td>
<td>Jan Ouwerkerk</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Daniel Kelly</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Felipe A. Calvo</td>
<td>ES</td>
</tr>
<tr>
<td></td>
<td>Alexander Molassiotis</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Lena Sharp</td>
<td>SE</td>
</tr>
<tr>
<td></td>
<td>Dirk Schrijvers</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Pierre Scalliet</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Charles Swanton</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Thomas Heelde</td>
<td>SE</td>
</tr>
<tr>
<td></td>
<td>Donal Hollywood</td>
<td>IE</td>
</tr>
<tr>
<td></td>
<td>Peter Campbell</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>Frédérique Penault-Llorca</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Vladimir Lazar</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Nadia Zaffaroni</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Christos Sotiriou</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Raffaella Giavazzi</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Anthony Chalmers</td>
<td>UK</td>
</tr>
</tbody>
</table>

## Translational research

<table>
<thead>
<tr>
<th>Track</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Evandro De Azambuja</td>
<td>BE</td>
</tr>
<tr>
<td></td>
<td>Pierre Mordant</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Joost Renier van der Vorst</td>
<td>NL</td>
</tr>
<tr>
<td></td>
<td>Simone Fulda</td>
<td>DE</td>
</tr>
<tr>
<td></td>
<td>Pierre Blanchard</td>
<td>FR</td>
</tr>
<tr>
<td></td>
<td>Lorenzo Livi</td>
<td>IT</td>
</tr>
<tr>
<td></td>
<td>Joan Seoane</td>
<td>ES</td>
</tr>
<tr>
<td></td>
<td>Alain Sund</td>
<td>SE</td>
</tr>
<tr>
<td></td>
<td>Ludwig P Muren</td>
<td>DK</td>
</tr>
<tr>
<td></td>
<td>Margaret Hutka</td>
<td>PL</td>
</tr>
<tr>
<td></td>
<td>Matthias Preusser</td>
<td>AT</td>
</tr>
<tr>
<td></td>
<td>Susana Banerjee</td>
<td>UK</td>
</tr>
<tr>
<td></td>
<td>David Olmos</td>
<td>UK</td>
</tr>
</tbody>
</table>

- Names in red denote Track Chairs
Call for Abstracts

Abstracts can only be submitted online at: eccamsterdam2013.ecco-org.eu/Event-Overview/AbstractSubmission

Abstracts submitted by regular mail, fax or E-mail will NOT be accepted.

Abstract submission deadline is 17 April 2013, 21:00 hrs Central European Time.

The European Cancer Congress 2013 abstract submission programme is available on the website: eccamsterdam2013.ecco-org.eu/Event-Overview/AbstractSubmission/Call-for-Abstracts

It is strongly advised that presenting authors should submit their abstract before the day of the deadline, otherwise authors may experience technical delay due to server overload.

The ECC 2013 Scientific Committee strongly encourages the submission of abstracts on Phase I, Phase II and large Phase III trials coming to an end or having new data available mid 2013. Please refer to “Late-Breaking Abstracts Policy & Regulations” on page 42.

Abstracts on case studies will be rejected.

1. ABSTRACT POLICIES AND REGULATIONS

With the submission of an abstract to ECC 2013, the first (presenting) author:

- Certifies to be an investigator with a substantial involvement in the clinical study presented in the abstract.
- Accepts responsibility for the accuracy of the submitted abstract (please proofread the abstract carefully prior to submission!)
- Accepts to be the contact person for all correspondence about the abstract and inform co-authors about its status.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the European Cancer Congress 2013.
- For important large studies, presented (in part) at previous meetings, authors are encouraged to provide updated data. Violation of this policy may result in a rejection of the submitted abstract.
- Certifies that the information in the abstract is for exclusive presentation in the ECC 2013 scientific programme and will not be presented as such during the congress at any industry-related satellite symposia.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Abstracts that include clinical trial data include the following information in the body of the abstract: Trial abbreviation, Trial Registry Number or ID, background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), Analysis, Trial status, Trial sponsor(s).
- Identifies any financial interest in products or processes described in the abstract. The presenting author is requested to tick the “Conflict of interest” box when submitting the abstract and to provide disclosure of interests and relationships through the abstract submission programme. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships.
- Releases the copyright to ECCO and gives permission for the abstract, when selected for presentation, to be published in the ECC 2013 Abstract Book with the European Journal of Cancer Supplement (in printed and electronic format), as well as on the ECCO website.
2. ABSTRACT PREPARATION AND SUBMISSION

a. Abstract format

- The title of the abstract should be brief, and in Sentence case, objectively describing the study. Do not use non-standard abbreviations and commercial names (generic names only).
- No more than 10 authors can be listed with institutional affiliations, cities and countries only. Mailing addresses and academic degrees should not be mentioned in the author’s list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract.
- Abstracts should be structured in such a way as to include the following 4 sections:
  1. Background: an introductory sentence indicating the purpose of the study
  2. Material and methods: a brief description of pertinent experimental procedures
  3. Results: a summary of the results of the research
- The on-line abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract, including spaces and table).
- Only one data table is permitted in the body of the abstract. Illustration and figures are not allowed and will be deleted if submitted.
- Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
- The abstract must be submitted in good English. The Scientific Committee reserve the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.

b. Abstract submission procedure

Abstracts must be submitted on-line, through the ECC 2013 website: eccamsterdam2013.ecco-org.eu/Event-Overview/Abstract-Submission/Call-for-Abstracts

ESSENTIAL INFORMATION

- When finished with the online submission, click the “FINAL SUBMISSION” button for the final submission of your abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
- If you need to edit your abstract at a later stage please click ‘SAVE AND CLOSE’. This button allows you to update your abstract before final submission. Please note: after clicking ‘SAVE AND CLOSE’, your abstract is NOT submitted. You need to return to the abstract submission page, finalise your abstract and click ‘FINAL SUBMISSION’.
- Within 48 hours of submission, the presenting author will receive an e-mail to confirm that ECCO has received the abstract. This confirmation of abstract does not mean your abstract has been selected for presentation.
- In case the confirmation from the ECC 2013 Secretariat is not received, please contact the secretariat (Pat.Vanhove@ecco-org.eu) within one week after the submission of the abstract.
- Submitting an abstract for presentation in the ECC 2013 does not constitute registration for the congress. Abstract presenters must register to attend the ECC 2013 by following the instructions for registration on the website.

Presentation preference
- oral, poster or no preference: the final decision on the presentation format will be made by the Scientific Committee.
**Topic category**
Please choose one main category and then select one sub category.

**Keywords**
Authors have to provide 3 keywords (different from category). The Scientific Committee has the authority to re-categorise and re-key the abstract.

For questions regarding the on-line submission process, e-mail: Pat.Vanhove@ecco-org.eu

3. **ABSTRACT SELECTION PROCESS**

Abstracts submitted for presentation in the ECC 2013 will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted.

The following presentation formats are applicable at the ECC 2013.

- **Oral presentation**: The abstract is selected for oral presentation at any of the proffered papers sessions. Abstracts of superior quality can be selected for presentation in a session where discussants will place the research findings into perspective.

- **Poster session**: Abstracts that have been selected for presentation in poster format will be displayed on poster boards. The posters are grouped by topic and are displayed for four hours. A specific time is devoted to poster viewing.

- **Poster discussion session**: Experts in the field are chosen to provide a themed overview and discussions of the findings from selected abstracts. First authors of abstracts that have been selected for poster discussion session will be invited to submit the poster electronically in advance of the congress (details will follow in due time). Abstracts will be made available two weeks before the congress. Presenting authors will be contacted to give their consent.

**Withdrawal of abstracts**: Abstracts submitted for presentation in the ECC 2013 can be withdrawn until Thursday 02 May 2013.

After this date, abstracts selected for oral or poster presentation should be presented. If the presenting author of a selected abstract cannot attend, (s)he should assign a replacement and inform ECCO of the replacement as soon as possible.

The presenting author will receive a letter with the result of the review and the Scientific Committee’s decision on the abstract by middle of June 2013.

4. **“LATE-BREAKING ABSTRACTS” POLICY AND REGULATIONS**

Late-Breaking Abstract online submission will be open from 24 July 2013 until 7 August 2013, 21:00 hrs Central European Time. Submit online at: eccamsterdam2013.ecco-org.eu/Event-Overview/Abstract-Submission

**Definition**
- Late-breaking abstracts should highlight novel and practice changing studies. The late-breaking abstract deadline is not intended to be merely an extension of the general submission deadline. It will focus on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress. Any abstract that fails to meet “Late-Breaking Abstract” requirements will not be considered.

- Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications; in each case the results should not have been fully available by the general abstract submission deadline.

- The data in the abstract must not be published (manuscript or abstract) prior to the congress.
Policy

- Late-Breaking Abstracts should follow the "Abstract policies and regulation" of the general abstract submission.

- Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the abstract submission deadline of 7 August 2013, will be considered for presentation at the ECC 2013.

- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please ask for special consideration by email.

- Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.

- Late-breaking abstracts will be considered for oral presentation either in proffered papers sessions or in one of the Presidential sessions. If a late-breaking abstract does not meet the criteria for oral presentation in one of these two sessions, the abstract will be rejected.

- Late-breaking abstracts will undergo formal peer-review evaluation by the Scientific Committee.

Submission

A call for late-breaking abstracts will be made in June. **Online submission will be open from 24 July 2013 until 7 August 2013 (21:00 hrs Central European Time)**

The first (presenting) author must:

- Submit a late-breaking abstract by the submission deadline of 7 August 2013

- Complete the section on the reasons why this abstract should be considered as late-breaking (in order for the abstract to be considered late breaking, this section must be completed)

- Ensure that submission of the abstract follows the general abstract submission guidelines and regulations and the specific guidelines listed above

- Ensure abstracts that include clinical trial data include the following information in the body of the abstract: Trial abbreviation, Trial Registry Number or ID background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), analysis, Trial status, Trial sponsor(s)

- Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating "results to follow" or similar deferment will not be considered

Selection

- Abstracts will be judged solely on the data submitted. The first (presenting) author will receive confirmation of acceptance or rejection before 20 August 2013.

5. EMBARGO POLICY FOR LATE-BREAKING, ORAL PRESENTATIONS AND ABSTRACTS SELECTED FOR MEDIA

- Abstracts submitted to the ECC 2013 are considered to be embargoed until the first day of the scientific programme.

- Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been published or presented at the ECC 2013.

- The first author and co-authors must not release the research/study to news media.

- If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.
### Abstract Topic Categories

<table>
<thead>
<tr>
<th>Topic</th>
<th>Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic Science</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aging and Cancer, Telomerase</td>
</tr>
<tr>
<td></td>
<td>Animal Models of Cancer</td>
</tr>
<tr>
<td></td>
<td>Cancer Cell Metabolism</td>
</tr>
<tr>
<td></td>
<td>Cancer Initiating Cells/Cancer Stem Cells</td>
</tr>
<tr>
<td></td>
<td>Cell Cycle, Cell Death, Senescence, Cell Proliferation</td>
</tr>
<tr>
<td></td>
<td>DNA Damage and Repair</td>
</tr>
<tr>
<td></td>
<td>Epigenetics</td>
</tr>
<tr>
<td></td>
<td>Functional Genomics</td>
</tr>
<tr>
<td></td>
<td>Gene Expression, Transcriptional Regulation</td>
</tr>
<tr>
<td></td>
<td>Genomic Alterations in Cancer</td>
</tr>
<tr>
<td></td>
<td>miRNA</td>
</tr>
<tr>
<td></td>
<td>Oncogenes</td>
</tr>
<tr>
<td></td>
<td>Receptors and Signal Transduction</td>
</tr>
<tr>
<td></td>
<td>Tumour Suppressor Genes</td>
</tr>
<tr>
<td></td>
<td>Tumour Angiogenesis</td>
</tr>
<tr>
<td></td>
<td>Tumour Microenvironment</td>
</tr>
<tr>
<td></td>
<td>Tumour Progression: Invasion and Metastasis</td>
</tr>
<tr>
<td></td>
<td>Tumour Immunology</td>
</tr>
<tr>
<td></td>
<td>Viral Oncogenesis</td>
</tr>
<tr>
<td><strong>Breast Cancer - Advanced Disease</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basic Science</td>
</tr>
<tr>
<td></td>
<td>Multi-Modality</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
</tr>
<tr>
<td></td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td></td>
<td>Translational Research</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td><strong>Breast Cancer - Early Disease</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basic Science</td>
</tr>
<tr>
<td></td>
<td>Multi-Modality</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
</tr>
<tr>
<td></td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td></td>
<td>Translational Research</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td><strong>Cancer in the Older Patient</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Multi-Modality</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
</tr>
<tr>
<td></td>
<td>Symptom Science</td>
</tr>
<tr>
<td></td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td><strong>Central Nervous System</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basic Science</td>
</tr>
<tr>
<td></td>
<td>Multi-Modality</td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
</tr>
<tr>
<td></td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td></td>
<td>Translational Research</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td><strong>Diagnosis/Biomarkers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expression Profiling</td>
</tr>
<tr>
<td></td>
<td>Predictive Biomarkers</td>
</tr>
<tr>
<td></td>
<td>Prognostic Biomarkers</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td><strong>Drug Development</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Angiogenic Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Apoptosis Inducers</td>
</tr>
<tr>
<td></td>
<td>Cyclins and CDKs</td>
</tr>
<tr>
<td></td>
<td>DNA Repair Mechanisms</td>
</tr>
<tr>
<td></td>
<td>Drug Design</td>
</tr>
<tr>
<td></td>
<td>Drug Resistance and Modifiers</td>
</tr>
<tr>
<td></td>
<td>Drug Screening</td>
</tr>
<tr>
<td></td>
<td>Drug Synthesis</td>
</tr>
<tr>
<td></td>
<td>Formulation Research</td>
</tr>
<tr>
<td></td>
<td>Immunological Targets</td>
</tr>
<tr>
<td></td>
<td>Monoclonal Antibodies and Targeted Toxins / Nuclides</td>
</tr>
<tr>
<td></td>
<td>Natural Products and Marine Compounds</td>
</tr>
<tr>
<td></td>
<td>New Molecular Targets</td>
</tr>
<tr>
<td></td>
<td>Radiation Interactive Agents</td>
</tr>
<tr>
<td></td>
<td>Signal Transduction Modulators</td>
</tr>
<tr>
<td></td>
<td>Telomerase-Targeting Agents</td>
</tr>
<tr>
<td></td>
<td>Topoisomerase Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Toxicology</td>
</tr>
<tr>
<td></td>
<td>Tubulin-Interacting Agents</td>
</tr>
<tr>
<td></td>
<td>Tumour Stem Cells</td>
</tr>
<tr>
<td></td>
<td>Tyrosine Kinase Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Vaccines</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td><strong>Epidemiology and Prevention</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Molecular Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Primary Prevention</td>
</tr>
<tr>
<td></td>
<td>Secondary Prevention</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>Topic Sub-Topic</td>
<td>Topic Sub-Topic</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Gastrointestinal Malignancies -Colorectal Cancer</strong></td>
<td><strong>Head and Neck Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Gastrointestinal Malignancies -Noncolorectal Cancer</strong></th>
<th><strong>Imaging</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>CT-Scan</td>
</tr>
<tr>
<td>Multi-Modality</td>
<td>Molecular Imaging</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>MRI</td>
</tr>
<tr>
<td>Surgery</td>
<td>New Methodologies</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Nuclear Medicine</td>
</tr>
<tr>
<td>Translational Research</td>
<td>US</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Genitourinary Malignancies -Other</strong></th>
<th><strong>Lung cancer - Localised / Local Regional</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Genitourinary Malignancies -Prostate Cancer</strong></th>
<th><strong>Lung Cancer - Metastatic</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Gynaecological Cancer</strong></th>
<th><strong>Melanoma and Skin Cancer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Haematological Malignancies and Myeloma</strong></th>
<th><strong>Oncology Nursing</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Advanced Nursing Roles</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Impact of Cancer on Patients and Families</td>
</tr>
<tr>
<td>Systemic Therapy</td>
<td>New Developments</td>
</tr>
<tr>
<td>Translational Research</td>
<td>Supportive and Palliative Care</td>
</tr>
<tr>
<td>Other</td>
<td>End of Life Care</td>
</tr>
<tr>
<td></td>
<td>Survivorship and Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Symptom Management</td>
</tr>
<tr>
<td></td>
<td>Transitions in Care</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>Topic Sub-Topic</td>
<td>Topic Sub-Topic</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Paediatric Oncology</td>
<td>Symptom Science</td>
</tr>
<tr>
<td>Public Health, Health Economics, Policy</td>
<td>Palliative Care</td>
</tr>
<tr>
<td>-</td>
<td>Psychosocial Aspects</td>
</tr>
<tr>
<td></td>
<td>Quality of Life</td>
</tr>
<tr>
<td></td>
<td>Supportive Care</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>Radiobiology/Radiation Physics/Radiotherapy Techniques</td>
<td>Translational Research</td>
</tr>
<tr>
<td>Advanced Technologies</td>
<td>Antibody Based Therapies</td>
</tr>
<tr>
<td>Biomarkers for Radiation Oncology</td>
<td>Biomarkers with Clinical Relevance</td>
</tr>
<tr>
<td>Clinical Radiation Physics</td>
<td>Cancer Genomics &amp; Bioinformatics</td>
</tr>
<tr>
<td>Clinical Radiobiology</td>
<td>Cancer Vaccine Therapies</td>
</tr>
<tr>
<td>Combined Treatments</td>
<td>Cellular Therapies</td>
</tr>
<tr>
<td>Frontiers in Radiation Oncology</td>
<td>Emerging Targets</td>
</tr>
<tr>
<td>Health Economics in Radiation Oncology</td>
<td>Epigenetics</td>
</tr>
<tr>
<td>Imaging for Radiotherapy</td>
<td>Inflammation and Cancer</td>
</tr>
<tr>
<td>Mathematics and IT for Radiation Oncology</td>
<td>Molecular Biology in the Clinic</td>
</tr>
<tr>
<td>Modification of Radiation Response</td>
<td>Molecular Pathology</td>
</tr>
<tr>
<td>Monitoring in Radiotherapy</td>
<td>Prognostic Biomarkers of Therapy Response</td>
</tr>
<tr>
<td>Multi-professional Team Development</td>
<td>Prognostic Value of Oncogenomics</td>
</tr>
<tr>
<td>Prediction and Stratification in Radiation Oncology</td>
<td>Signalling Pathways</td>
</tr>
<tr>
<td>Professional Development</td>
<td>Tumour Microenvironment</td>
</tr>
<tr>
<td>Quality Assurance</td>
<td>Other</td>
</tr>
<tr>
<td>Radiation Physics</td>
<td>Onco-Technology</td>
</tr>
<tr>
<td>Radiobiology</td>
<td>Basic Medical Engineering</td>
</tr>
<tr>
<td>Radiotherapy Outcome Assessment</td>
<td>Clinical Medical Engineering</td>
</tr>
<tr>
<td>Radiotherapy Techniques</td>
<td>Computational Models of Biological Systems</td>
</tr>
<tr>
<td>Radiotherapy Technologies</td>
<td>DNA Detection Technologies</td>
</tr>
<tr>
<td>Technology assessment in Radiation Oncology</td>
<td>Integrated Biology</td>
</tr>
<tr>
<td>Treatment Planning</td>
<td>Internet Technology for Oncology</td>
</tr>
<tr>
<td>Other</td>
<td>Nanotechnology</td>
</tr>
<tr>
<td>Regulatory/Trial Methodology/Pharmacy</td>
<td>New Imaging Technologies</td>
</tr>
<tr>
<td>Surgical Techniques</td>
<td>New Non-Ionizing Radiation Treatment Technology</td>
</tr>
<tr>
<td>Sarcoma: Soft Tissue and Bone</td>
<td>New Treatment Technologies: Ionising Radiation Treatment Technology</td>
</tr>
<tr>
<td></td>
<td>Novel Communication Systems</td>
</tr>
<tr>
<td></td>
<td>Novel IT for Oncology</td>
</tr>
<tr>
<td></td>
<td>Novel Navigation Systems</td>
</tr>
<tr>
<td></td>
<td>Oncology Information Systems</td>
</tr>
<tr>
<td></td>
<td>Patient Safety Systems Technology</td>
</tr>
<tr>
<td></td>
<td>Proteomics/Mass Spectrometry</td>
</tr>
<tr>
<td></td>
<td>RNA Detection Technologies</td>
</tr>
<tr>
<td></td>
<td>Telemetry and Cyber Physical Systems for Oncology</td>
</tr>
<tr>
<td></td>
<td>Tele-Oncology</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
</tbody>
</table>
Fellowship Grants & Educational Awards

1. The European Cancer Congress Fellowship Grants

Through the generosity of the European Cancer Congress 2013 Sponsors, a number of Fellowship Grants are offered to young researchers (doctors and basic scientists) from countries with limited resources to attend the Congress.

To meet the requirements to be considered for a fellowship grant, the applicant should:

- Submit an abstract for the European Cancer Congress 2013. Applicants whose abstracts have been accepted for an oral or poster presentation at the ECC 2013 will be considered first.
- Be under the age of 40 and have a primary focus in clinical or experimental oncology.
- Provide a letter of support from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support, including a copy of the submitted abstract.
- Provide a two page CV (including date of birth).

The deadline for receipt of applications is 17 April 2013 (abstract submission deadline). Incomplete applications will not be considered.

Each Fellowship Grant shall be worth a free registration, free accommodation for a maximum of 3 nights and reimbursement of travel costs up to a maximum of €500 (reimbursement after the Congress).

Please complete the online application form on the ECCO website at:

eccamsterdam2013.ecco-org.eu/Event-Overview/Fellowship-Grants-Educational-Awards/Congress-Fellowship-Grants

2. ECCO/EJC Young Investigator’s Award

ECCO – the European CanCer Organisation and EJC - European Journal of Cancer are pleased to announce the ECCO/EJC Young Investigator’s Award, to be presented at the Congress.

The ECCO/EJC Young Investigator’s Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for recent original work in cancer research, treatment or care.

The following application criteria will apply:

- Candidates should be junior (within 5 years of completion of PhD or specialist training).
- Candidates should have completed the submitted work in the period between April 2011 and April 2013.
- Submissions should be sent in by the candidate together with a reference letter from their Head of Department.
- The work may be the result of individual research or the result of a thesis completed in the field of basic, translational or clinical research.
- Candidates should commit themselves to write an original paper in English on the scientific work carried out (for publication in EJC).

The application should include the following documents:

- A summary of the research work (maximum 2 pages) and copies of recently published or submitted manuscripts of the applicant’s work, to be submitted in English.
- A curriculum vitae and a list of publications.
- A supporting letter from the Head of Department.
Applications will be reviewed by the European Cancer Congress Committee Chairs and the Editor-in-Chief of EJC.

The winner of the ECCO/EJC Young Investigator’s Award will receive a prize of €4 000, free registration, free accommodation for a maximum of 3 nights, reimbursement of travel costs up to a maximum of €500 (reimbursement after the Congress) and the opportunity to give an oral presentation of the work at the ECC 2013.

**Deadline for applications: May 15, 2013.**

Applications should be sent to Simona Androni, Scientific Programme Co-ordinator via Email: simona.androni@ecco-org.eu

Successful applicants will be notified in the course of July 2013.

### 3. Fellowship Grants for Oncology Nurses and Radiotherapy Technicians

Through the generosity of the European Cancer Congress Sponsors a small number of fellowship grants will be awarded to nurses and radiotherapy technicians from countries with limited resources to attend the ECC 2013 in Amsterdam. Applications from Practising Clinical Nurses would be especially welcome.

Applicants should submit a short CV and a letter explaining the benefit for them in attending the Congress. The application should be accompanied by a letter from the Head of Department stating that the applicant is not the recipient of any other financial support.

Applicants must be fluent in English.

Fellowship applications should be submitted to Simona Androni **before the deadline of 17 April 2013.**

Email: simona.androni@ecco-org.eu
ESTRO AWARDS

ESTRO - VARIAN AWARD

A prize of 2500 euros will be given to a radiotherapy professional for research in the field of Radiobiology, Radiation Physics, Clinical Radiotherapy or Radiation Technology.

CRITERIA FOR ELIGIBILITY

1. Candidates should be ESTRO members, having completed the submitted work in the previous year.

2. Submissions should be brought forward by the candidates or their department heads and may be work done as an individual piece of research or as a thesis complete in the field of biological, physical and clinical research.

3. They should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.

4. Candidates should submit:
   • A curriculum vitae and a list of publications
   • A copy of the abstract on the project which should have been submitted for the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (indicate abstract title and submitting author with your application)
   • An English summary of their work (max 2 pages)

ESTRO - ACCURAY AWARD

A prize of 2500 euros will be given to a radiotherapy professional for research in the field of “High Precision Radiotherapy”. Awardees may be qualified in the field of Clinical Radiotherapy, Radiation Physics, Radiation Technology or Radiobiology.

CRITERIA FOR ELIGIBILITY

1. Candidates should be ESTRO Members, having completed the submitted work in the previous or current year.

2. Submissions should be brought forward by the candidates and may be work done as an individual piece of research or as a thesis completed in the field of biological, physical or clinical research.

3. Candidates should submit:
   • A curriculum vitae and a list of publications
   • A copy of the abstract on the project which should have been submitted for the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (indicate abstract title and submitting author with your application)
   • An English summary of their work (max 2 pages)

APPLICATIONS FOR THE ABOVE LISTED AWARDS ARE TO BE ADDRESSED TO:

Eralda Azizaj
ESTRO Programme Manager
Rue Martin V 40, 1200 Brussels, Belgium

Tel: +32 2 775 93 40
E-mail: eralda.azizaj@estro.org

DEADLINE FOR SUBMISSION: 1 APRIL 2013
Put your knowledge to the test on 28 September 2013

ESMO Examination

Why take the ESMO Examination?

- Knowledge-based assessment tool for practicing medical oncologists
- Benchmark for medical oncologists in training
- Qualification as a professional, with national recognition in some European countries, who possesses the knowledge, skills and aptitude essential for the optimal treatment of cancer patients
- Become an ESMO Certified Member
- First step to collect ESMO-MORA, CME points for recertification every 5 years

Registration opens: 3 January 2013
Registration deadline: 22 July 2013

The Examination will take place on Saturday, 28 September during the European Cancer Congress in Amsterdam, with simultaneous sessions in various locations.

Sample questions from previous exams now available online.

Visit esmo.org to find out more and register now.
### Registration

Register online on: [eccamsterdam2013.ecco-org.eu/Registration](eccamsterdam2013.ecco-org.eu/Registration)

#### REGISTRATION FEES

(Please tick appropriate box)

<table>
<thead>
<tr>
<th>'Deadline' applies to both receipt of registration and payment</th>
<th>Early Rate Deadline: 09 April 2013</th>
<th>Regular Rate Deadline: 06 August 2013</th>
<th>Late Rate Deadline: 20 September 2013</th>
<th>Onsite Rate****** As of 21 September 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members*</td>
<td>□ 479 EUR</td>
<td>□ 699 EUR</td>
<td>□ 999 EUR</td>
<td>1199 EUR</td>
</tr>
<tr>
<td>Non-Member</td>
<td>□ 699 EUR</td>
<td>□ 999 EUR</td>
<td>□ 1099 EUR</td>
<td>1199 EUR</td>
</tr>
<tr>
<td>Junior Participant**</td>
<td>□ 175 EUR</td>
<td>□ 199 EUR</td>
<td>□ 220 EUR</td>
<td>235 EUR</td>
</tr>
<tr>
<td>Emerging Economy Rate***</td>
<td>□ 130 EUR</td>
<td>Not available</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>Nursing Members*****</td>
<td>□ 250 EUR</td>
<td>□ 355 EUR</td>
<td>□ 460 EUR</td>
<td>685 EUR</td>
</tr>
<tr>
<td>Nursing Non-Members</td>
<td>□ 375 EUR</td>
<td>□ 485 EUR</td>
<td>□ 585 EUR</td>
<td>685 EUR</td>
</tr>
<tr>
<td>Patient Advocates</td>
<td>□ 125 EUR</td>
<td>□ 150 EUR</td>
<td>□ 170 EUR</td>
<td>190 EUR</td>
</tr>
<tr>
<td>Webcasts: ***** Non-members</td>
<td>□ 55 EUR</td>
<td>□ 55 EUR</td>
<td>□ 55 EUR</td>
<td>55 EUR</td>
</tr>
</tbody>
</table>

All registration fees include local VAT.

* Discounted membership rates apply for individuals who are member of one of the following professional associations: EACR, ESMO, ESSO, ESTRO, SIOPE, EANO, EAU, EORTC, ESGO, ESO, ESOP, EUSOMA, BIG, EANM, EBMT, ECL, Europa Donna, Europa Uomo, Euroskin, FAC, Myeloma Euronet, OECI, UICC. **Stating association and membership number is obligatory.**

** Confirmation of ‘in training’ status and a letter from the Head of Department is required. These documents have to be sent to the European Cancer Congress Secretariat by fax +32 2 775 02 00. Junior ESMO members need not send a letter but are required to state their membership reference number.

*** Emerging Economy Rate is applied to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: [http://data.worldbank.org/about/country-classifications/country-and-lending-groups](http://data.worldbank.org/about/country-classifications/country-and-lending-groups)

**** Exclusive to members of EONS only

***** Available to participants only

******* Registration at the venue will open on 26 September 2013. Between 21 and 25 September included, only online registration will be possible at the Onsite Rate.
Exhibition & Sponsorship

The recognised multidisciplinary setting of the European Cancer Congress will once again provide ideal surroundings for participants to leverage knowledge, promote education and build awareness about oncology - placing the patient at the heart of all our efforts and discussions. The Congress strives to further the role of multidisciplinary oncology by encouraging participation and interaction between all oncology professions, irrespective of their focus.

For information on sponsorship and exhibition opportunities, please contact:
Bruno De Man
Phone: +32 2 775 02 04
Email: bruno.deman@ecco-org.eu

To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECC 2013 website at: eccamsterdam2013.ecco-org.eu

Exhibitor Spotlight Theatre

The following new Spotlight Sessions provide a unique opportunity to directly liaise with congress delegates, educate them about latest products and showcase latest developments.

These Spotlight Sessions will be found in the Exhibition area.

| Slot 1 | Saturday 28-09-2013 | 12:30 – 13:30 | GSK Oncology |
| Slot 2 | Saturday 28-09-2013 | 12:30 – 13:30 | Celgene |
| Slot 3 | Sunday 29-09-2013  | 12:30 – 13:30 | Helsinn Healthcare |
| Slot 4 | Sunday 29-09-2013  | 12:30 – 13:30 | Caris Life Sciences |
| Slot 5 | Monday 30-09-2013  | 12:30 – 13:30 | Available |
| Slot 6 | Monday 30-09-2013  | 12:30 – 13:30 | Available |
General Information

Accommodation

MCI Amsterdam Office has been appointed as the official local housing partner for the European Cancer Congress 2013 and is offering hotel accommodation and other services for both groups and individuals. Booking Accommodation is open since October 2012.

For all accommodation queries and information, please contact:

MCI Amsterdam Office
Jan van Goyenkade 11
NL-1075 HP Amsterdam
The Netherlands
Tel: +31 20 679 3411
Fax: +31 20 673 7306
E-mail: amsterdam2013@mc-group.com

We kindly ask you to contact the appointed local housing partner directly. The Congress secretariat cannot provide accommodation-related information or handle any such related requests.

A list of hotels will be provided on the website: eccamsterdam2013.ecco-org.eu

Opening Ceremony

The Opening Ceremony for the European Cancer Congress will take place on Friday 27 September from 19:30 onwards in the Congress Centre.

The keynote speech will be given by a world-renowned expert on the future of cancer therapy and research. As customary, the National Organising Committee will introduce Amsterdam and The Netherlands to the participants.

Following the ceremony, there will be a Networking Reception - an opportunity for Society Members and participants to meet and discuss their latest data in cancer as well as meeting top experts in the field.

ECCO and its Founding Members

As founding members of ECCO - the European CanCer Organisation, ESMO, ESTRO, ESSO, EACR, EONS and SIOP, have joined together once again to form a powerful combination of seven senior organisations endorsing multidisciplinarity as the way forward to best improve the prevention, diagnosis, treatment and care of cancer patients.

The ECC 2013 provides the opportunity to:

■ Attend Society General Assemblies (Sunday 29 September at 8:15)
■ Join in Society Sessions (see programme for full details)
■ Meet Society Secretariats at their exhibition stands
■ Network and discuss the day’s exciting developments in comfort at the Exclusive Members’ Lounges
■ Fast-track to becoming a new Society member by signing up at the stand

Congress Update Service

The Congress Update Service is the official electronic newsletter of the European Cancer Congress. Designed specifically to help keep you fully informed about the latest scientific programme highlights and exciting developments in the lead up to the Congress.

Launching nine months in advance of the Congress, this newsletter is sent to all registrants and appears on the Congress website: eccamsterdam.ecco-org.eu

If you wish to subscribe, please let us know: ecc2013-comms@ecco-org.eu
Official Congress Newspaper – OncoPost & OncoPeople

A very popular feature of the Congress, three issues of the official congress newspaper OncoPost & OncoPeople, will be produced for ECC 2013. Comprising up-to-the-minute news, features, reports, interviews and next-day highlights, this newspaper is a must-read for all participants. All three issues will be made readily available throughout the conference centre to keep participants fully up-to-date.

OncoPost & OncoPeople is produced by ECCO - the European CanCer Organisation and published by Deutscher Ärzte-Verlag.

To purchase advertising in this publication, please contact Katrin Groos. Tel. +49 (0)2234 7011 – 304 Groos@aerzteverlag.de

Official Carrier

Save up to 20% on travel with the Star Alliance network
The Star Alliance™ member airlines have been appointed as the Official Airline Network for the European Cancer Congress, Amsterdam, 27 September – 1 October 2013.

Registered participants travelling to the event and one accompanying person may qualify for a Star Alliance Conventions Plus discount of up to 20%, depending on fare and class of travel booked. To obtain the discount, please quote the event code SK01A51 when calling the reservation office of a participating Star Alliance member airline.

For booking office information please visit: www.staralliance.com/conventionsplus

The participating airlines for this event will be announced soon on the website: eccamsterdam2013.ecco-org.eu

Please note: For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

Insurance

The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

Language and Translation

The official language of the Congress is English. No simultaneous translation will be provided.

Lunch and Refreshments

Lunch or refreshments are not included as part of the registration fee.

Transportation

Amsterdam RAI is easy to reach by both public transport or by car and has ample parking facilities on and outside its site. Amsterdam RAI is situated 8 minutes from Amsterdam's city centre and 15 minutes from Schiphol Airport.

- By train: station Amsterdam RAI
- By tram, metro or bus: from Amsterdam Central Station: tram 4, metro 51. From Amstel railway station: metro 51 and bus 65. From Amsterdam Sloterdijk station: metro 50.
- By car: The RAI is signposted on roads signs on the ring road after approaching Amsterdam from the A1 motorway (Amersfoort/Amsterdam), the A2 (Utrecht/Amsterdam) or the A4 (Den Haag [The Hague]/Amsterdam). Amsterdam RAI is situated right next to the ring road (Exit 9). The RAI's car parks are signposted immediately after leaving the ring road.

Participants registered for the entire duration of the European Cancer Congress are entitled to one free public transport ticket giving access to public transport in Amsterdam during the Congress and are encouraged to use public transport as much as possible.
Top 10 Reasons to Attend ECC 2013

1. The European Cancer Congress is the premier cancer congress in Europe.

2. Recognised impact: This series of congresses represents the largest European platform for presenting the latest, ground-breaking data, with a late-breaking submission policy to capture even more practice-changing abstracts.

3. Global visibility: Building on past successes and widespread international coverage garnered by previous Congresses, the Congress in Amsterdam promises an even stronger media campaign to increase exposure.

4. No limits: The European Cancer Congress is without boundaries. In 2011, a record number of participants from 110 countries attended Stockholm. ECC 2013 will continue this trend to advance multidisciplinarity throughout Europe and beyond.

5. Top quality content: The comprehensive Scientific Programme of excellence is being devised based on your input and feedback by leading scientific experts in our field, ensuring exceptional quality and educational opportunity.

6. Widespread appeal: The wide-ranging Scientific Tracks guarantee a multidisciplinary and multi-professional appeal unique to the European Cancer Congress, creating a level playing field for all stakeholders in oncology.

7. Continued education: The European Cancer Congress is the largest CME ACOE Accredited event in Europe, guaranteeing high quality and unbiased educational activities. The credits gained are recognised by most national CME authorities in Europe.

8. Tackling challenging issues: Our Congress is the only European cancer meeting to promote and foster continued improvement at EU level through a dedicated Oncopolicy Track, specifically tailored to address issues of prime importance to the European cancer community head-on.

9. Mixing new & old: ECC 2013 will also incorporate the usual favourites including the not-to-be-missed legendary Oxford style debates, educational symposia, the highly topical teaching lectures and much more.

10. Host city Amsterdam is one of the greatest small cities in the world. From its charming canals and world-famous museums, to its diverse culture, and good transport system, the capital of the Netherlands is one of the most romantic and beautiful cities in Europe.
SAVE UP TO 20% ON GETTING TO YOUR CONVENTION WITH CONVENTIONS PLUS

It’s easy to save money on your flights if you fly the Star Alliance network. Simply quote the event code SK01A51 when you make your booking with any Star Alliance member airline and you’ll automatically get a discount of up to 20%.

The Star Alliance network has 27 member airlines with over 21,900 flights a day so we can offer you a lot more choice when planning your travel. For more information about our member airlines and contact details, please visit our website at staralliance.com/conventionsplus
Leading Oncology Titles from Elsevier

- Radiotherapy & Oncology
  - Latest Impact Factor: 5.580
- EJSO
  - Latest Impact Factor: 2.499
- European Journal of Oncology Nursing
  - Latest Impact Factor: 1.410
- Cancer Treatment
  - Latest Impact Factor: 6.054
- Genitourinary Cancer
  - Latest Impact Factor: 2.605
- The Breast
  - Latest Impact Factor: 2.491
- Breast Cancer
  - Latest Impact Factor: 2.375
- Cancer Treatment Communications
  - New!
- Journal of Cancer Policy
  - New!

Peer-reviewed and interdisciplinary / original research and clinical trials / informative editorials and state-of-the-art reviews

Download FREE Sample Issues / Sign-up for free e-alerts / AND MUCH MORE

Visit the journals online today go to: www.journals.elsevierhealth.com

Access Elsevier oncology journals through the Health Advance Journals App!
Your time is well spent with THE LANCET Oncology

Look to The Lancet Oncology for original research, expert reviews, informative commentary, and breaking news – all with a clear, independent perspective – and stay well informed about the developments shaping the oncology field today.

Whether you are a reader or an author, The Lancet Oncology has valuable time-saving resources for you:

- Read the latest research and news at thelancet.com/oncology
- Download our new Lancet iPad app at apple.com/iTunes
- Stay informed with e-tables of contents and news alerts at thelancet.com
- Gain greater insight from monthly podcasts available on iTunes and at thelancet.com
- Submit a manuscript at ees.elsevier.com/thelancetoncology
- Get your original research published within 8 weeks of submission

THE LANCET Oncology
The independent and authoritative voice in global clinical oncology

The Lancet is a registered trademark of Elsevier Properties SA used under licence.
2013 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology

Call for Nominations

ECCO – the European CanCer Organisation and the Pezcoller Foundation are pleased to announce the Call for Nominations for the 2013 Pezcoller Foundation-ECCO Recognition for Contribution to Oncology.

For 2013, in collaboration with ECCO – The European CanCer Organisation, the Pezcoller Foundation-ECCO Recognition for Contribution to Oncology will be awarded to a single individual for his/her professional life dedication to the improvement of cancer treatment, care and research. The award is open to all professions and specialties within the oncology field.

Nominations will be accepted for candidates irrespective of race, gender or nationality. Institutions, groups or associations are not eligible. Self-nominations will not be considered. Candidates must be nominated on the official form by one who is, or has been, affiliated with a university or medical institution.

A curriculum vitae and description of the candidate’s professional contribution to the field of oncology should be included with the application form.

Nominators are requested to keep their nomination confidential and to refrain from informing the nominee. The awardee will be selected by an International Committee appointed by the ECCO President with the agreement of the Council of the Pezcoller Foundation. The decision concerning the 2013 winner will be taken in April 2013.

The award consists of a prize of 30.000 EUR and a commemorative plaque. The Award Ceremonies will be held in Rovereto (Italy), on 13 September 2013 and in Amsterdam, During the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress as a Plenary Lecture to be delivered during the Presidential Session of Sunday 29 September 2013.

More Information:
For more information about the nomination process and to submit a completed form and support documentation please contact
Carine Lecoq:
Tel: + 32 2 775 29 31, Fax: +32 2 775 02 00,
Email: carine@ecco-org.eu

Nomination forms can be downloaded at:
www.ecco-org.eu (select “Education” > “Awards”) and must be completed and received by 31 March 2013.

About the Pezcoller Foundation

The Pezcoller Foundation was established in 1980 through a most generous donation from Professor Alessio Pezcoller, a dedicated Italian surgeon, who devoted his life to his profession. Professor Pezcoller not only made important contributions to medicine but through his generosity and foresight, provided his lifetime’s savings for others to do likewise.

Formerly, until 1997, the Pezcoller Foundation presented an award in collaboration with the European School of Oncology (ESO). The Pezcoller Foundation-ECCO Recognition for Contribution to Oncology builds on this tradition.

Award Committee

Prof. Cornelis van de Velde (NL), President of ECCO, Chair
Prof. Davide Bassi (IT), President of the Pezcoller Foundation
Prof. Mario Paolo Colombo (IT), Istituto Nazionale Tumori
Prof. Sara Faithfull (UK), University of Surrey
Prof. Giampaolo Tortora (IT), University of Verona
Prof. Vincenzo Valentini (IT), Universita Cattolica S. Cuore of Rome

Ex-officio:
Mr. Michel Ballieu, ECCO Chief Executive Officer
Dr. Alberto Costa, ESO Director

The representatives are appointed by their respective Board of Directors and are not eligible for receiving the award.
The European Cancer Congress 2013, Amsterdam, 27 September - 1 October 2013

In partnership with ECCO, ESMO, ESTRO, ESSO 33, EACR, EONS, and SIOPE

ECCO, Avenue E. Mounier 83,
B-1200 Brussels, Belgium

Phone: +32 (0)2 775 02 01
Fax: +32 (0) 2 775 02 00

www.ecco-org.eu